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Intronic hexanucleotide repeat expansion in the C9orf72 gene is a leading cause of 
frontotemporal lobar degeneration (FTLD) with amyotrophic lateral sclerosis (ALS). 
Among several hypotheses, reduced expression of C9orf72 has been proposed as a 
possible disease mechanism. However, the function of C9orf72 remains unclear.  
Here, I have presented data that begins to elucidate the function of C9orf72 at a cellular 
and organismal level. My data has found that C9orf72 binds SMCR8 and WDR41 to 
form a protein complex. Each component of this complex is important for the stability 
of the entire complex, as loss of any one of these three protein causes a decrease of other 
complex components. SMCR8 protein is almost completely lost in the C9orf72-/- 
mouse tissues, but has little change in the WDR41-/- mice, whereas C9orf72 levels are 
decreased by loss of either SMCR8 or WDR41. I have also shown that the C9orf72 
complex interacts with the Ulk1-FIP200 complex, as well as the cytoskeletal component 
tubulin, and several Rab GTPases. Furthermore, I provide evidence that mTOR 
phosphorylation and localization is mis-regulated and that AKT phosphorylation is also 
altered in SMCR8-/- cells, leading to mis-regulated autophagy-lysosome functions. 
Finally, I have created knockout mice for C9orf72, SMCR8, and WDR41 using 
 CRISPR-Cas9 and preliminarily characterized the phenotypes that these mice exhibit. 
Altogether, my data support a role for the C9orf72-SMCR8-WDR41 complex in 
regulating the autophagy-lysosome pathway and maintaining proper immune 
regulation.  
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CHAPTER 1 
 
AUTOPHAGY-LYSOSOME DYSFUNCTION IN AMYOTROPHIC LATERAL 
SCLEROSIS AND FRONTOTEMPORAL LOBAR DEGENERATION  
 
This work was submitted 12 February 2017 to be published by InTech and included in 
their forthcoming textbook Lysosomes- associated diseases and methods to study its 
function. ISBN 978-953-51-5281-1.  
 
1.1 Introduction 
Proper degradation machinery is necessary for neuronal survival, and disruption 
of lysosomal function is sufficient to cause neurodegeneration[1–4]. To recycle cellular 
material, cells use two major pathways: autophagy for organelles and long-lived 
proteins and the ubiquitin-proteasome system (UPS) for short-lived proteins[5,6]. 
Autophagy consists of three pathways that each ultimately delivers cellular contents to 
the lysosome for degradation. The pathways are chaperone-mediated autophagy 
(CMA), which uses HSC70 to recognize specific misfolded proteins; microautophagy, 
which directly invaginates material into the lysosome; and macroautophagy, which is 
responsible for the degradation of organelles, protein aggregates, and large protein 
complexes. Macroautophagy (hereafter referred to as autophagy) is the most common 
pathway. The autophagy pathways and molecular mechanisms have been recently 
reviewed elsewhere[7,8]. The presence of protein aggregates in most neurodegenerative 
diseases suggests common underlying problem in protein degradation systems. Here we 
summarize the connection between the autophagy-lysosome pathway and two 
neurodegenerative diseases Amyotrophic Lateral Sclerosis (ALS) and Frontal-
Temporal Lobar Degeneration (FTLD)[9].  
ALS is characterized by the loss of upper and lower motor neurons resulting in 
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progressive weakness and ultimately paralysis. Patients survive a median of 3-5 years 
from disease onset [10]. FTLD is characterized by the degeneration of neurons in the 
frontal cortex and anterior temporal lobes. This degeneration leads to changes in 
behavior and language impairment. The subtypes of FTLD can be distinguished by the 
prominent symptoms, which reflect the area affected by neuron loss[11,12]. The 
subtypes are behavioral variant frontotemporal dementia (bvFTD), semantic dementia 
(SD), and primary non-fluent aphasia (PNFA). bvFTD, the most common subtype, is 
characterized by changes in behavior such as disinhibition, loss of empathy, impaired 
social skills, and decline in personality. SD is characterized by impaired language 
comprehension, and PNFA disrupts speech production[9]. These subtypes often overlap 
and can additionally include Parkinson’s disease like symptoms. Patients survive for a 
median of 7-11 years after diagnosis. There are no treatments for FTLD[9].  ALS and 
FTLD symptoms are often present in the same patient, an indication that these diseases 
have shared etiology[13,14] 
Each disease is also subdivided by molecular pathology depending on the 
primary components of inclusion bodies: Tau, TDP-43, FUS, and ubiquitin in FTLD 
and SOD1, TDP-43 (with or without C9orf72 dipeptide repeats), and FUS in ALS[9,15]. 
In 2006, both ALS and FTLD were found to have neuronal inclusions composed largely 
of TDP-43, an RNA-binding protein, that are also ubiquitin and p62  positive, 
suggesting that these aggregates were tagged for degradation[16–18]. Additionally, 
genetic mutations have since been discovered that can lead to the development of both 
ALS and FTLD. Thus, these two diseases are linked by clinical concurrence, molecular 
pathology, and genetic overlap[13,14,19].  
As many new genes have been identified for FTLD and ALS in the last decade, 
studies have revealed a common theme of these genes functioning in the lysosomal 
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network (Figure 1). Some mutations, such as GRN, TMEM106B, CHMP2B and VCP 
are associated with disrupted lysosomes and multivesicular bodies (MVB). Other 
mutations, such as in p62/SQSTM1, OPTN, UBQLN2, and TBK1 directly disrupt 
selective autophagy and therefore prevent cargo from being degraded. Other mutations 
have a more complex relationship with autophagy and lysosome function, such as the 
RNA-binding proteins TARDBP and FUS. Here, we will discuss the genetic causes of 
ALS and FTLD in more detail with specific emphasis on lysosomal and autophagy 
impairment (Figure 1).  
 
 
 
Figure 1-1: Functions of the ALS/FTLD genes in the autophagy-lysosome 
pathway.  Many genes associated with ALS/FTLD play critical roles in the endosome-
lysosomal pathway, regulate lysosomal functions or affect autophagy pathway directly 
or indirectly 
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1.2 Mutations affecting the endolysosome pathway: PGRN, TMEM106B, CHMP2B, 
and VCP  
Progranulin (PGRN) 
The most common cause of familial FTLD  with ubiquitin positive aggregates 
is mutation of the GRN gene, which accounts for 10% of all FTLD cases and ~25% of 
familial FTLD (20,[21,22]. About 70 mutations in the GRN gene have been linked to 
FTLD, most of which have been shown or predicted to decrease PGRN protein level or 
disrupt secretion of PGRN[20,21,23,24]. While FTLD is caused by haploinsufficiency 
of PGRN, a more serve neurodegeneration is caused by homozygous loss of PGRN. 
This complete loss of PGRN results in neuronal ceroid lipofuscinosis (NCL), a type of 
lysosome storage disorder (LSD) characterized by the build-up of autofluorescent 
lipofuscin[25,26]. These findings suggest that loss of function mutations in the GRN 
gene causes neurodegenerative diseases in a dose-dependent manner and is important 
for lysosome function.  
The function of PGRN is still under investigation: It is known to be a secreted 
glycoprotein comprised of 7.5 granulin repeats with pleiotropic roles, including protein 
homeostasis, inflammation, and neuronal survival and outgrowth [27]. Recently several 
lines of evidence suggest that it plays a vital role in lysosome function. First, GRN has 
been found to be regulated with other lysosomal genes[28]. Furthermore, GRN mRNA 
and PGRN protein levels are upregulated in response to lysosome or autophagy 
inhibition[29]. Finally, PGRN was found to be delivered to the lysosome[30,31]. PGRN 
reaches the lysosome through at two independent pathways. In one path, PGRN’s 
extreme C-terminus binds the sorting receptor sortilin, which carries PGRN to the 
lysosome[30,32]. In the second pathway, PGRN binds prosaposin, and they are 
transported to the lysosome together by the cation-independent mannose-6-phosphate 
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receptor (CI-M6PR) and Low-Density Lipoprotein Receptor-Related Protein 1, LRP1 
[31].  
Mouse models of PGRN deficiency have consistently found increased levels of 
ubiquitin and p62, an adaptor for delivering cargo to the autophagosome[33], buildup 
of lipofuscin and its protein components saposin D and SCMAS, electron-dense storage 
granules, all of which suggest lysosome impairment[31,34–36]. Several models also 
found aggregation of TDP-43, similar to what is seen in FTLD patients[34,37,38]. 
Furthermore, PGRN-deficient mouse models also phenocopy FTLD symptoms such as 
decreased social interaction and mild learning/memory defects[35,38–40]. The presence 
of clear lysosomal problems in mouse models and in patients with complete loss of 
PGRN suggest that PGRN is necessary for lysosome function. FTLD- patients with 
GRN mutations also exhibit typical pathological features of NCL pathology[36], 
suggesting FTLD and NCL caused by PGRN mutations are pathologically linked and 
lysosomal dysfunction is one of underlying disease mechanisms for FTLD-GRN. 
However, how PGRN regulates lysosomal function remains to be investigated.  
TMEM106B 
Another gene associated with FTLD is TMEM106B, which is the only identified 
risk factor for FTLD with GRN mutations[41–44]. TMEM106B was also found to 
increase risk in patients with C9orf72 hexanucleotide repeat expansions[45,46]. The 
TMEM106B SNP associated with FTLD increases the mRNA and protein levels of 
TMEM106B[36,44,47]. TMEM106B is a single pass type II transmembrane protein that 
localizes to the late endosome and lysosome[47–49]. Cellular studies on TMEM106B 
have pointed to roles in lysosome trafficking and lysosomal stress response[50,51]. 
Overexpression of TMEM106B in cells disrupts lysosome morphology and 
function[47,48]. Furthermore, when a transgenic TMEM106B mouse line was crossed 
with a PGRN deficient mouse, the lysosome abnormalities and lipofuscin accumulation 
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seen in PGRN deficient mouse were exacerbated[52]. The connection between 
TMEM106B’s role at the lysosome and as a risk factor for FTLD with GRN mutations 
further highlights the importance of the lysosome pathway in FTLD etiology.  
CHMP2B 
The sole mutation identified to cause FTLD with ubiquitin positive, but Tau, 
TDP-43, and FUS negative inclusions, occurs in the gene CHMP2B [53,54]. CHMP2B 
has also been found to cause rare cases of ALS[55]. CHMP2B functions in the ESCRT-
III complex, involved in MVB formation to deliver cargo from endocytic pathway to 
lysosomes[56,57]. The mutations identified create an early termination of the protein, 
resulting in an unregulated CHMP2B truncation that is unable to recruit VPS4 to recycle 
the ESCRT-III complex to new sites of MVB formation[58,59]. With ESCRT-III still 
engaged on the MVB, MVB-lysosome fusion cannot take place[54,60–62]. 
Furthermore, CHMP2B mutations impair autophagosome maturation, possibly through 
the disruption of amphisome formation between autophagosome and late endosomes 
[63–66]. Mouse models of CHMP2B mutations replicate both ALS and FTLD 
pathology, whereas CHMP2B knockout mice do not show neurodegenerative 
phenotypes, implicating a gain of function disease mechanism[67–70]. Similar to the 
PGRN deficiency mouse models, CHMP2B mutations cause protein inclusions and 
accumulation of autofluorescent aggregates in the frontal cortex, reminiscent of 
lysosome storage disorders[71]. Thus, FTLD-associated mutations in CHMP2B impair 
the endo-lysosomal pathway, which itself may cause additional defects in 
autophagy[66,69], providing additional evidence that disruption of the autophagy-
lysosome pathway may drive ALS and FTLD.  
 
VCP 
Valosin-Containing Protein (VCP) has been implicated in several diseases 
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including FTLD [22,72–76], ALS [77], and Charcot Marie Tooth disease, a genetic 
peripheral nerve disorder [78]. VCP is an AAA+-ATPase that delivers and unfolds 
ubiquitinated proteins, as well as ERAD (endoplasmic-reticulum-associated protein 
degradation) substrates, at the proteasome [79–83]. Furthermore, VCP binds to 
clathrin and EEA1 to regulate the size and selectivity of endosomes [83–85]. 
Pharmacological inactivation of VCP as well as VCP knockdown inhibits MVB 
formation and blocks autophagosome maturation, resulting in accumulated LC3-II, 
ubiquitin, and p62 levels along with cytoplasmic TDP-43 aggregation [86–88]. 
Disease-associated mutants of VCP present similar phenotypes in transgenic mouse 
models, whereas complete loss of VCP is embryonic lethal [86,89–91]. Finally, VCP 
mutants inhibit the autophagic turnover of stress granules, which may be relevant to 
the accumulation of TDP-43 positive aggregates found in patients with VCP mutations 
[76,92,93]. The precise mechanism that halts autophagosome maturation in VCP 
mutations remains unclear, though MVB dysfunction may play a role[66]. VCP’s role 
in MVB formation and the observations of altered autophagic flux suggests that loss of 
VCP function may cause ALS, FTLD, and other related neurodegenerative diseases by 
impairing the lysosome-autophagy pathway. 
 
1.3 Autophagy Adaptor proteins  
Further evidence that ALS and FTLD are linked to autophagy and lysosome 
disruption comes from mutations that directly affect several autophagy adaptor proteins 
and their regulation. Genetic mutations in the adaptor proteins p62/SQSTM1, UBQLN2, 
and OPTN have been shown to contribute to rare cases of ALS[94–99]  and 
FTLD[100,101].These adaptor proteins all contain an ubiquitin-associated (UBA) 
domain, which is able to bind poly-ubiquitin conjugated proteins that are tagged for 
 8 
degradation by either the UPS or autophagy. The autophagy adaptors then associate 
with LC3 on the autophagosome to deliver the cargo for degradation through autophagy-
lysosome pathway.  
p62/SQSTM1 
p62/SQSTM1 (p62) positive inclusions have been observed in patient tissue 
samples in both ALS and FTLD [18,102–104]. The association of p62 with inclusions 
suggests that the inclusion body has been targeted for degradation and the accumulation 
of such inclusions suggests that there may be defective mechanisms for protein turnover 
[33,105,106]. p62 bridges autophagy substrates to the autophagosome by interacting 
with ubiquitinated proteins via its UBA domain [107] and LC3 with its LC3-interacting 
region (LIR) [33,108,109].  
p62 is activated by phosphorylation at Ser407 by ULK1, allowing further 
phosphorylation by Casein Kinase 2 or TANK-Binding Kinase 1 (TBK1), which 
increases p62’s affinity for poly-ubiquitinated cargo[110–113]. p62 acts within the 
selective autophagy system by aggregating proteins and organelles together for the 
autophagosome to enclose[106,114]. These aggregated cargos are then subject to 
autophagy[115,116]. While p62 accumulation and association with protein aggregates 
broadly suggests a defect in autophagy, mutations in p62 directly link selective 
autophagy impairment to neurodegeneration.  
The p62 mutations identified in ALS and FTLD patients disrupt aggregate 
formation or decrease the amount of p62 protein produced, leading to loss of 
function[117–119]. Homozygous mutation of p62 cause adolescence/childhood-onset 
neurodegeneration with a defect in mitochondrial depolarization response due to 
impaired autophagy[120]. Thus, a loss of normal p62 function in autophagy leads to 
neurodegeneration in a dose-dependent manner, with earlier onset correlating to lower 
levels of functional p62.  
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In addition to its role in autophagy, p62 also links ubiquitinated cargo to the 
proteasome through its UBA domain[106] and mediates the degradation of the protein 
via the UPS, indicating that p62 plays multiple roles in proteostasis[121].   
Ubiquilin2 
Another adaptor protein implicated in ALS and FTLD is Ubiquilin2 
(UBQLN2)[95,122]. Similar to p62, UBQLN2 is able to recognize ubiquitinated 
proteins and bind them via its UBA domain[123]. The UBA domain is also required for 
UBQLN2 to associate with the autophagosome, though unlike p62 and OTPN, 
UBQLN2 does not directly recognize LC3[124,125]. 
Knockdown of UBQLN2 in culture reduced autophagosome formation and 
inhibited lysosomal degradation of mitochondria[124,125]. This loss of UBQLN2 also 
sensitizes cells to starvation-induced death in an autophagy-dependent manner[124]. 
Interestingly, UBQLN2 binds directly to TDP-43 holo-protein and C-terminal 
fragments and may regulate the levels of TDP-43 in the cell independent of 
ubiquitin[126]. Indeed, overexpression of UBQLN2 in culture can reduce aggregation 
of TDP-43[126].  
Many of the disease-associated mutations map to the proline-rich domain in 
UBQLN2, which is important in mediating protein-protein interactions[95,127]. 
Furthermore, mutations in UBQLN2 have a reduced binding to hnRNPA1, a RNA-
binding protein implicated in ALS. Interestingly, ALS-associated mutations in 
hnRNPA1 also disrupt this binding[128], confirming that the interaction of autophagy 
adaptors with their intended cargos is important for neuronal survival.  
UBQLN2 knockout in a rodent model showed no neuronal loss, implying that 
loss of function is not the disease mechanism or that other autophagy adaptors are able 
to compensate for its loss in vivo. Transgenic animals with the ALS/FTLD-associated 
UBQLN2 mutations produce ubiquitin, p62, and UBLQN2 positive puncta accompanied 
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by neuronal loss, cognitive defects, and motor impairment[129–131]. Increased 
expression of the wildtype UBQLN2 also causes neurodegeneration in a rodent 
model[132]. Thus unlike mutations in p62, UBQLN2 mutations appear to have a gain 
of function mechanism that impairs proper protein degradation by autophagy.  
In addition to its function in the autophagy pathway, UBLQN2 binds to the 
proteasome through its ubiquitin-like (UBL) domain to deliver poly-ubiquitinated 
proteins and ERAD substrates to the proteasome for degradation[133]. A role of 
UBQLN2 in delivering protein aggregates to proteasome mediated degradation via 
HSP70 has been recently demonstrated[134]. UBQLN2 also function together with 
other ALS/FTLD-related proteins, such as regulating endosome constitution with 
OPTN[135]  and delivering ERAD substrates to the proteasome with VCP[136]. 
Optineurin 
Rare mutations in OPTN are also associated with both ALS [97,99] as well as 
FTLD[101]. These mutations are expected to decrease the level of OPTN protein, 
suggesting a loss of function resulting in disease[101]. In total, 1-4% of familial ALS 
cases are linked to mutations in OPTN[137]. OPTN, like p62 and UBQLN2, binds to 
poly-ubiquitin labeled proteins via a UBA domain[138]. OPTN also binds LC3 through 
a LIR to connect cargo to autophagosomes. Damaged mitochondria specifically recruit 
OPTN to induce mitophagy[139]. In support of a loss of function model for OPTN, 
depletion of OTPN in zebrafish causes motor defects[140]. 
OPTN also interacts with several other proteins associated with ALS. The E3 
ubiquitin ligase HACE1 ubiquitinates OPTN to promote binding to p62 which forms a 
complex that enhances autophagic flux[141]. Similarly, phosphorylation of OPTN 
byTBK1 increases the interaction of OPTN and p62 to the same effect[138,142]. OPTN 
also binds directly to SOD1 aggregates independently of ubiquitination. Mutations in 
OPTN do not affect this interaction, but do impair autophagic clearance of SOD1 protein 
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aggregates through an unknown mechanism[138,140]. 
Mutation in OPTN had previously been linked to Primary Open-Angle 
Glaucoma (POAG) where these mutations were shown to decrease basal autophagy and 
inhibit autophagic flux upon autophagy induction[143]. Thus Mutations in OPTN have 
clear links to multiple neurodegenerative disease with consistent impairment in the 
autophagy pathway. How mutations in the same gene and similar cellular impairments 
can lead distinct clinical outcomes remains unclear. 
TBK1 
TBK1 has recently been associated with both ALS and 
FTLD[96,98,101,110,111,144–147]. TBK1 has functions in autophagy and in 
inflammation[148]. Regarding its function in autophagy, TBK1 phosphorylates p62 and 
OPTN to increase their binding to LC3 and ubiquitin, respectively[138,142]. Many of 
the discovered disease-associated mutations are expected to decrease TBK1 protein 
level, suggesting a loss of function model[96,101].  
While TBK1 interacts with both p62 and OPTN, TBK1 and OPTN share several 
additional connections. Like OPTN, some mutations in TBK1 also cause 
glaucoma[149]. Furthermore, the mutation in OPTN that causes POAG enhances the 
binding of OPTN to TBK1, which may sequester TBK1 and prevent it from carrying 
out its normal function[142]. Finally, both TBK1 and OPTN are required specifically 
for mitophagy, with depletion of either component or expression of an ALS-associated 
mutant impairing mitophagy[150]. Taken together, mutations in TBK1 cause decreased 
protein expression and prevent TBK1 from regulating p62 and OPTN in their autophagy 
roles, again supporting a role of autophagy in preventing ALS and FTLD.  
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1.4 Mutations in C9orf72 
The most common known cause of both ALS and FTLD was discovered to be a 
hexanucleotide intronic repeat expansion in the gene C9orf72[151–153]. This repeat 
expansion is found in 18-25% of familial FTLD, 40% of familial ALS, and 4-8% of 
sporadic ALS and FTLD combined[154,155]. While patients with C9orf72 mutations 
display TDP-43 positive aggregates, they also have separate inclusions unique to this 
genetic mutation. These ubiquitin, p62, and occasionally UBQLN2 positive inclusions 
also contain dipeptide repeats generated from the repeat expansion[156–160]. Three 
molecular mechanisms of disease have been proposed: toxic gain of function of RNA 
repeats, gain of function of dipeptide repeats (DPR) produced by repeat-associated non-
ATG translation, and haploinsufficiency of the C9orf72 protein.  
RNA-repeats transcribed from the repeat expansion form nuclear foci and 
sequester many RNA-binding proteins, including several RNA-binding protein already 
implicated in ALS and FTLD[161–164]. In addition to disrupting RNA-binding proteins 
directly, the RNA foci disrupt nucleocytoplasmic transport[165,166]. Furthermore, 
nuclear TDP-43 is depleted in a fly model expressing C9orf72 repeats, which may allow 
TDP-43 to accumulate and aggregate in the cytosol[167]. This model is of interest 
because it connects to the RNA-binding proteins already associated with ALS and 
FTLD, such as TDP-43, which aggregates in both diseases. A second model suggests 
that five distinct DPRs are translated and can also alter nucleocytoplasmic transport to 
block TDP-43 import[168,169]  as well as disrupt membrane-less, phase-separated 
organelles such as the nucleolus, nuclear pore, and stress granules[170]. 
Haploinsufficiency was also proposed as a disease mechanism[153,161,171–
173]. Early C9orf72-depletion models in c. elegans and zebrafish showed motor 
dysfunction, supporting this model[174,175]. However, a neuronal specific C9orf72 
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knockout mouse showed no such phenotype[176]. Complete C9orf72 knockout mice 
also do not show much neurodegeneration, but instead exhibit severe immune problems 
similar to autoimmune disorders[177–182]. 
Interestingly, C9orf72 has been reported to play a role in autophagy and 
lysosome regulation. While many of the reports suggest that C9orf72 and its binding 
partners, SMCR8 and WDR41, play a role in regulating autophagy initiation or 
maturation, likely via the FIP200/ULK1 complex, the precise mechanism remains 
uncertain [180,183–187]. Other reports suggests that C9orf72 plays a role in mTOR and 
TFEB signaling[187,188], in stress granule assembly[189], or in actin dynamics[190].  
 
1.5 RNA-binding proteins: TDP-43 and FUS 
The RNA-binding proteins TDP-43 and FUS have been closely associated with 
ALS and FTLD. Pathogenic TDP-43 or FUS aggregates are present in both conditions, 
though mutations in these genes result primarily in ALS[191]. Both proteins travel 
between the nucleus and cytoplasm as they regulate gene splicing, mRNA stability and 
trafficking, and stress granule dynamics[192,193].  
As both TDP-43 and FUS regulate the RNA from thousands of genes, many 
cellular problems could be anticipated. However, several lines of evidence have pointed 
out a role in regulating and challenging the autophagy pathway[194]. 
TDP-43 
The identification of TDP-43 as the main component of protein aggregates in 
both ALS and FTLD spurred the awareness that ALS and FTLD had some underlying 
similarities[16,17]. Interestingly, mutations in TARDBP, the gene encoding TDP-43, 
lead overwhelmingly to ALS or ALS/FTLD, but not to FTLD alone[195,196]. While 
soluble TDP-43 can be cleared by chaperone-mediated autophagy through its 
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interaction with Hsc70[197], TDP-43 positive stress granules and aggregates are cleared 
by macroautophagy[198,199]. 
In addition being a substrate of autophagy, TDP-43 may play a direct role in 
regulating autophagy through its transcriptional regulation of ATG7[200]. As TDP-43 
is sequestered in protein aggregates, it can no longer regulate ATG7 transcription, 
impairing autophagy initiation and further promoting TDP-43 accumulation[199,200]. 
In a similar manner, TDP-43 also regulates the mRNA for RPTOR and DCTN1[198].  
RPTOR encodes a component of the mTOR complex, and loss of RPTOR upregulates 
lysosome and autophagy biogenesis[198]. However, reduced DCTN1 mRNA, which 
encodes Dynactin, a key component of autophagosome-lysosome fusion, leads to the 
accumulation of autophagosomes, preventing the turnover of aggregated TDP-43[198]. 
TDP-43 additionally plays an important role in stress granule dynamics and 
mutations in TARDBP have been shown to increase the stability of stress granules, 
possibly allowing them to become irreversible protein aggregates[199,201–204]. In 
support of this prolonged stress granule hypothesis, mutations in VCP decrease stress 
granule turnover by autophagy, leading to TDP-43 positive inclusion[92].  
The interaction of TDP-43 with autophagy suggests a complex regulatory 
balance between the two under normal conditions. In disease states, a feedforward 
mechanism of TDP-43 sequestration into stress granules and aggregates followed by 
impaired autophagy could drive pathogenesis of ALS and FTLD[9,203].  
FUS 
Like TARDBP, mutations in FUS have been linked more closely to ALS, though 
protein aggregates positive for FUS appear in both ALS and FTLD[9]. FUS positive 
inclusions account for about 5-10% of FTLD cases[9] and 1% of ALS cases[15]. Several 
proposed mechanisms link FUS to disruption of the autophagy and lysosome pathway. 
First, the presence of FUS positive aggregates in both familial and sporadic cases of 
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ALS and FTLD suggest FUS may be particularly susceptible to aggregation. FUS is 
also involved in autoregulation, which could allow for a feed-forward cycle of increased 
FUS production followed by cytosolic accumulation and aggregation[199,205].  
Additionally, mutations in FUS have been linked to altered stress granule 
dynamics[206,207]. FUS positive stress granules were found to be degraded by 
autophagy; however, stress granules containing mutant FUS were more stable and 
prevented stress granules disassembly[199]. As with TDP-43, stabilized stress granules 
may promote insoluble aggregate formation[203,208–210].This increases the burden on 
the autophagy pathway and may drive further cell damage. A recent study also found 
that ALS-associated mutant FUS was able to inhibit the early steps of autophasosome 
formation, leading to impaired autophagy flux[211]. Many of these studies found that 
enhancing autophagy, genetically or pharmaceutically, was able to reduce FUS-positive 
inclusions and prevent cellular toxicity[199,206,211]. While less well understood than 
TDP-43, the RNA-binding protein FUS seems to play a similar cellular role as TDP-43, 
including regulating the dynamics of stress granules. Besides increased burden on 
autophagy due to stabilized stress granules, FUS may also play a more direct role in 
autophagy impairment.  
 
1.6 Microtubule-Associated Protein Tau 
30% of familial FTLD cases are caused by mutations in MAPT, encoding the 
protein tau[212]. These cases are characterized by the presence of tau aggregates 
positive for ubiquitin and p62, suggesting impaired degradation of accumulated 
tau[121,213]. Generic disruption of autophagy cargo selection is sufficient to cause 
aggregation of pathogenic tau[214]. The tau protein is most well-known for its 
association with Alzheimer’s disease, when it also forms aggregates and is accompanied 
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by neurodegeneration of the hippocampus[215]. How Alzheimer’s disease and FTLD 
patients have overlapping cellular pathology but develop different clinical symptoms 
remains unclear. 
Full length tau can be degraded by the UPS in an ubiquitin-dependent and 
independent manner[121,216,217], whereas misfolded or phosphorylated tau is sent to 
the autophagy pathway[218]. Generally, tau aggregation and toxicity correlates with 
autophagy activity, where enhanced autophagy rescues neurodegeneration and 
impairment exacerbates the symptoms[219–222]. Likewise, modulating TFEB to 
increase lysosome biogenesis prevents the accumulation of tau[223].  
Tau is a microtubule binding protein that helps to stabilize axonal 
microtubules[224,225]. Small increases in unbound tau induces aggregation, suggesting 
that even mild impairment of the UPS or autophagy-lysosome pathway could lead to 
pathological tau accumulation[226,227]. In support of this idea, Niemann-Pick disease, 
another lysosome storage disorder, also develops tau aggregates[228,229]. These points 
show that tau is highly dependent on autophagy and lysosome function and disruption 
of this pathway may drive tau aggregation. Furthermore, since tau has a role in 
microtubule stability, disrupted cytoskeletal dynamics and trafficking have also been 
proposed as a disease mechanism. Since lysosomes, endosomes, MVB, and 
autophagosomes all move along microtubules, any disruptions would affect their ability 
to maintain proteostasis[230].   
 
1.7 Discussion 
ALS and FTLD are distinct clinical disorders that share overlapping symptoms, 
pathology and genetics. Many of the causative genetic mutations and risk factors result 
in disruption of the lysosome and autophagy pathway (Figure 1). Some disease-
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associated mutants or alleles directly impact lysosomal function through yet unknown 
mechanisms, such as PGRN and TMEM106B, or through disruption of the late stages of 
the endo-lysosome pathway, as VCP and CHMP2B mutations are proposed to do. 
Beyond the lysosome, there are also many mutations in adaptor proteins that impair 
selective autophagy, including p62/SQSTM1, OPTN, and UBQLN2. The misregulation 
of these adaptors is sufficient to induce neurodegeneration, as seen with TBK1 mutants. 
Finally, some mutations have a more intricate relationship to the autophagy and 
lysosome pathway that future research will have to address, including C9orf72 protein, 
repeat-associated RNA foci, and dipeptide repeats, as well as the microtubule binding 
protein Tau and the RNA-binding proteins TDP-43 and FUS.  
Identifying the underlying cellular problems that lead to disease is an important 
step in being able to distinguish disorders and subtypes that may ultimately require 
distinct diagnosis and treatment. The genetic analysis of ALS and FTLD has improved 
our understanding of this disease spectrum and may inform us of the broad problems 
that underlie both familial and sporadic ALS and FTLD. The consistent impairment of 
cellular clearance pathways by ALS and FTLD-associated mutations points to a disease 
mechanism that is likely to be shared in undiscovered genetic causes, as well as 
environmental risk factors, that account for the cases of ALS and FTLD that have no 
known cause.   
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CHAPTER 2 
 
THE ALS/FTLD ASSOCIATED PROTEIN C9ORF72 ASSOCIATES WITH 
SMCR8 AND WDR41 TO REGULATE THE AUTOPHAGY-LYSOSOME 
PATHWAY 
 
This work was submitted 6 May 2016 and first published 18 May 2016 
DOI10.1186/s40478-016-0324-5. The manuscript was published as Sullivan PM, Zhou 
X, Robins AM, Kim D, Smolka M, and Hu F. The ALS/FTLD associated protein 
C9orf72 associates with SMCR8 and WDR41 to regulate the autophagy-lysosome 
pathway. Acta Neuropathologica Communications. 2016;4:51. DOI: 10.1186/s40478-
016-0324-5.  
 
2.1 Abstract  
Hexanucleotide repeat expansion in the C9orf72 gene is a leading cause of 
frontotemporal lobar degeneration (FTLD) with amyotrophic lateral sclerosis (ALS). 
Reduced expression of C9orf72 has been proposed as a possible disease mechanism. 
However, the cellular function of C9orf72 remains to be characterized. Here we report 
the identification of two binding partners of C9orf72: SMCR8 and WDR41. We show 
that WDR41 interacts with the C9orf72/SMCR8 heterodimer and WDR41 is tightly 
associated with the Golgi complex. We further demonstrate that 
C9orf72/SMCR8/WDR41 associates with the FIP200/ Ulk1 complex, which is essential 
for autophagy initiation. C9orf72 deficient mice, generated using the CRISPR/Cas9 
system, show severe inflammation in multiple organs, including lymph node, spleen and 
liver. Lymph node enlargement and severe splenomegaly are accompanied with 
macrophage infiltration. Increased levels of autophagy and lysosomal proteins and 
autophagy defects were detected in both the spleen and liver of C9orf72 deficient mice, 
supporting an in vivo role of C9orf72 in regulating the autophagy/lysosome pathway. 
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In summary, our study elucidates potential physiological functions of C9orf72 and 
disease mechanisms of ALS/FTLD. 
 
2.2 Introduction  
Frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis 
(ALS) are two devastating neurodegenerative diseases, which due to overlaps in clinical 
presentations, pathological features, and genetic causes, are considered two 
manifestations of a continuous disease spectrum [1-6]. 
Many novel genes have been recently associated with ALS/FTLD [5, 7]. Among 
these, hexanucleotide repeat expansion in the C9orf72 gene has been shown to be the 
main cause of ALS/FTLD [8-10], for which three disease mechanisms have been 
proposed: toxicity of RNA foci formed by RNA repeats, toxicity induced by dipeptide 
repeat aggregation as a result of repeat associated non-ATG mediated RNA translation 
(RAN), and reduced expression of the C9orf72 gene [11, 12]. Recently, many animal 
models have been established to investigate repeat associated gain of toxicity [13-18] 
as well as the physiological functions of C9orf72 in mammals. While neuron and glia 
specific C9orf72 ablation or intracerebral mRNA knockdown does not seem to cause 
motor neuron disease in mouse models [19, 20], two recent studies on whole body 
C9orf72 deficient mice demonstrate that C9orf72 deficiency results in severe immune 
dysregulation [21, 22], suggesting that loss of C9orf72 function could lead to mis-
regulated inflammatory responses. 
Despite many attempts at characterizing the exact molecular function of 
C9orf72, its cellular role is still not entirely clear. Bioinformatics studies have predicted 
C9orf72 to be a member of DENN domain containing proteins which typically function 
as guanine exchange factors for Rab GTPases, key regulators of membrane trafficking 
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in eukaryotic cells [23, 24].  One study has demonstrated physical interactions between 
C9orf72 and Rab7 and Rab11, GTPases involved in late endosome maturation or 
endosome recycling, respectively, and a role of C9orf72 in autophagy regulation [25]. 
However, direct regulation of these Rab GTPases by C9orf72 was not demonstrated in 
this study [25].   
In order to gain insight into C9orf72 function, we performed a proteomic screen 
for C9orf72 binding partners. We showed that C9orf72 forms a tight complex with 
SMCR8, another DENN domain containing protein [24], and WDR41, a WD40 repeat 
protein. We further demonstrated the physical interaction between 
C9orf72/SMCR8/WDR41 and the FIP200/Ulk1/ATG13/ATG101 complex, which is an 
essential regulator of autophagy initiation. Our results are consistent with two recent 
reports on the C9orf72/SMCR8/WDR41 interaction published while this manuscript 
was under preparation [26, 27]. Furthermore, our data from C9orf72 deficient mice 
support a role of C9orf72 in immune regulation and the autophagy-lysosome pathway. 
 
2.3 Results 
C9orf72 forms a complex with SMCR8 and WDR41 
In humans, two C9orf72 protein isoforms are generated from three alternatively 
spliced transcripts, a long form (C9-L) and a short form (C9-S), with multiple studies 
showing that the protein and mRNA level of the C9-L form are decreased in C9/ALS 
patients [28-30]. To decipher the protein interaction network of C9orf72, a SILAC 
(stable isotope labeling of amino acids in cell culture) based proteomic screen was 
performed in the neuroblastoma cells line neuro-2a (N2a) using GFP-C9orf72 (C9-L) 
as the bait and GFP as a control (Fig. 2-1a, Fig. 2-S1). Several proteins were found to 
be enriched in the C9orf72 immunoprecipitations (IPs) (Fig. 2-1b, Table 2-S1). The top 
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two hits from the screen were SMCR8 and WDR41, two proteins of unknown functions 
(Fig. 2-1b). Interestingly, like C9orf72, SMCR8 was also predicted to contain a DENN 
domain [24]. The interaction between C9orf72, SMCR8, and WDR41 was verified 
using co-IPs in transfected HEK293T cells (Fig. 2-2a-c). SMCR8 strongly interacts with 
GFP-C9orf72 but not GFP in the co-IP experiment (Fig. 2-2a). Moreover, co-expression 
of C9orf72 consistently increases the level of SMCR8, suggesting that C9orf72 might 
stabilize overexpressed SMCR8. However, the short isoform of human C9orf72 (C9-S) 
does not bind SMCR8 (Fig. 2-2a). Thus we focus on the C9-L form for the rest of the 
study (hereafter referred to as C9orf72). While we failed to detect any interaction 
between WDR41 and C9orf72 or SMCR8 when WDR41 is expressed with either 
C9orf72 or SMCR8 alone, WDR41 strongly co-immunoprecipitates with C9orf72 and 
SMCR8 when C9orf72 and SMCR8 are co-expressed, suggesting that WDR41 interacts 
only with the C9orf72/SMCR8 heterodimer (Fig. 2-2b-c).  
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Figure 2-1: SILAC proteomic screen for C9orf72 binding partners. 
a. Schematic workflow of SILAC proteomic screen used to identify C9orf72 protein 
interactions.  b. Volcano plot of SILAC hits. Hits with more than 10 peptides are plotted. 
Top hits identified in the heavy fraction are highlighted.  
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Protein 
Log2 fold 
change 
(GFP/GFP-
C9orf72 IP) P Value Count Count H Count L 
WDR41 -5.43 1.85E-07 23 22 1 
3110043O21RIK -4.55 1.58E-07 144 114 30 
SMCR8 -4.17 1.75E-06 64 57 7 
VDAC3 -3.58 3.89E-07 29 25 4 
SLC25A4 -2.52 3.87E-06 20 15 5 
SLC25A5 -2.49 5.23E-06 50 33 17 
CHCHD3 -2.15 8.81E-05 14 11 3 
SLC25A12 -2.11 1.64E-06 29 22 7 
IMMT -2.09 4.91E-05 27 23 4 
SLC3A2 -1.64 6.02E-06 16 11 5 
SLC25A12 -1.60 3.73E-06 17 13 4 
LOC100046151 -1.54 7.94E-06 14 7 7 
FAR1 -1.52 9.92E-05 14 11 3 
SLC25A11 -1.52 4.62E-06 11 8 3 
DNAJA1 -1.49 1.15E-05 38 29 9 
GCN1L1 -1.41 4.18E-04 18 16 2 
DNAJB11 -1.39 1.82E-05 14 9 5 
DNAJA2 -1.39 2.42E-05 27 21 6 
KARS -1.32 3.61E-03 13 10 3 
ASS1 -1.30 6.00E-04 13 10 3 
TUBA4A -1.25 4.60E-05 11 6 5 
SLC25A4 -1.24 3.49E-05 59 34 25 
MTAP1B -1.18 9.49E-05 79 57 22 
SLC25A4 -1.11 1.27E-04 24 13 11 
NSF -1.09 1.41E-03 11 7 4 
2310079N02RIK -1.02 3.44E-04 15 10 5 
TUBA1A -1.01 2.73E-04 30 17 13 
 
Table 2-S1: List of hits from the SILAC proteomic screen. Proteins with more than 
ten peptides and Log2 fold change (GFP/GFP-C9orf72) <-1.00 are listed. Count: total 
number of peptides identified; Count H: number of peptides in the heavy fraction; Count 
L: number of peptides in the light fraction.  
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Figure 2-2: Co-immunoprecipitation between C9orf72, SMCR8 and WDR41 
a. GFP-tagged human C9orf72 isoform I (GFP-C9-L) or isoform II (GFP-C9-S) were 
overexpressed with SMCR8-myc in HEK293T cells and immunoprecipitated by anti-
GFP beads. b. SMCR8-GFP and WDR41-myc were coexpressed with or without 
FLAG-C9-L and the lysates were immunoprecipitated using anti-GFP antibodies. c. 
GFP-C9-L and FLAG-WDR41 were co-expressed with or without SMCR8-myc as 
indicated and the lysates were immunoprecipitated using anti-GFP antibodies.  
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Cellular localization of C9orf72, SMCR8 and WDR41 
To gain insight into the cellular function of the C9orf72/SMCR8/WDR41 
complex, we expressed these proteins in HeLa cells and examined their distribution 
within the cell. Both C9orf72 and SMCR8 show diffuse cytoplasmic localization, when 
expressed alone or together (Fig. 2-3a and 2-3b). Nuclear localization was observed for 
C9orf72, especially the GFP-tagged C9orf72 but not SMCR8 (Fig. 2-3a and 2-3b). 
WDR41 also shows diffuse cytoplasmic distribution (Fig. 2-3a and 2-3c). However, 
careful examination reveals enrichment of WDR41 at the cis-Golgi, which is confirmed 
when labelled by the cis-Golgi protein GPP130 (Fig. 2-3c). This is further supported by 
treatment of cells with BrefeldinA, which causes the Golgi to collapse. Even after such 
treatment, WDR41 remains colocalized with GPP130, indicating that WDR41 is tightly 
associated with the Golgi membrane. Similar results were obtained after treatment with 
nocodazole, a microtubule destabilizing drug that causes the Golgi to disperse (Fig. 2-
3c).    
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Figure 2-3: Cellular localization of C9orf72, SMCR8 and WDR41. 
a. HeLa cells were transfected with FLAG-C9orf72 (C9-L), SMCR8-myc or WDR41-
GFP. Cells were stained with anti-FLAG or anti-myc to visualize FLAG-C9orf72 or 
SMCR8-myc, respectively. Maximum projection images from confocal sections are 
shown. Scale bar=10µm b. HeLa cells were transfected with GFP-C9orf72 and 
SMCR8-myc. Cells were stained with anti-myc antibodies to visualize SMCR8-myc. c. 
WDR41-GFP expressing HeLa cells were treated with DMSO control, 0.3mM 
BrefeldinA (BFA), or 20mM Nocodazole for 2 hours. Cells were stained with anti-
GPP130 antibodies to label cis-Golgi. Single confocal images are shown for b and c. 
Scale bar=10µm. 
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Interaction of C9orf72/SMCR8/WDR41 with the FIP200 autophagy initiation 
complex 
A previously reported proteomics screen identified SMCR8 as a binding partner 
for FIP200 (also called RB1CC1) [31], a protein involved in autophagy initiation [32]. 
However, the interaction between SMCR8 and FIP200 is barely detectable by co-IP 
when only these two proteins are overexpressed (Fig. 2-4a).  Interestingly, we found 
that co-transfection of C9orf72 and SMCR8 allows much stronger binding of SMCR8 
to FIP200, which is further enhanced by WDR41 overexpression, suggesting that 
C9orf72/SMCR8/WDR41 forms a ternary complex to interact with FIP200 (Fig. 2-4a). 
The weaker binding between SMCR8 and FIP200 when  SMCR8 is expressed alone in 
HEK293T cells is most likely explained by very low endogenous levels of C9orf72 and 
WDR41 (Fig. 2-4a and Fig. 2-S1). Ulk1, a kinase that interacts with FIP200 in the 
autophagy initiation complex [32], binds the C9orf72/SMCR8/WDR41 in a similar 
manner as FIP200 (Fig. 2-4a). Furthermore, C9orf72, SMCR8 and WDR41 are all 
detected in the FIP200 immunoprecipitates (Fig. 2-4b).  ATG13 and ATG101, two other 
proteins associated with FIP200/Ulk1 also interact with C9orf72/SMCR8/WDR41 (Fig. 
2-4c and 2-4d). These data support that the formation of the C9orf72/SMCR8/WDR41 
complex allows their interaction with the FIP200/Ulk1/ATG13/ATG101 complex (Fig. 
2-4e).  
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Figure 2-4: The C9orf72/SMCR8/WDR41 complex interacts with FIP200/Ulk1.  a. 
Co-immunoprecipitation between C9orf72/SMCR8/WDR41 and FIP200 and Ulk1.  
HEK293T cells were transfected with FLAG-FIP200 and C9orf72, SMCR8 and/or 
WDR41 as indicated. Cells were lysed 40hrs after transfection and lysates were 
 49 
(continued from previous page) immunoprecipated with anti-GFP antibodies.  Lysates 
and immunoprecipitates were analyzed by Western blots as indicated. * indicated non-
specific bands recognized by anti SMCR8 antibodies in the IP products. Representative 
images from 3 independent experiments are shown. b. Co-immunoprecipitation 
between C9orf72/SMCR8/WDR41 and FIP200. HEK293T cells were transfected as 
indicated and lysed and immunoprecipitated using anti-FLAG antibodies.  Lysates and 
immunoprecipitates were analyzed by Western blots. c, d. Co-immunoprecipitation 
between C9orf72/SMCR8/WDR41 and ATG101 (c) or ATG13 (d). HEK293T cells 
were transfected as indicated and lysed and immunoprecipitated using anti-GFP 
antibodies. Lysates and immunoprecipitates were analyzed by Western blots. e. 
Schematic drawing of the interaction between C9orf72/SMCR8/WDR41 and the 
FIP200/Ulk1 complex. WDR41 interacts with the C9orf72/SMCR8 dimer to form 
ternary complex, which then interacts with the FIP200/Ulk1/ATG13/ATG101 complex. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-S1: Levels of endogenous versus overexpressed C9orf72 in N2a and 
HEK293T cells. N2a (a) and HEK293T (b) cells were transfected with GFP control or 
GFP-C9orf72. Cells were lysed two days after transfection and lysates were subjected 
to Western blot using anti-C9orf72 antibodies (Proteintech) to determine the levels of 
endogenous versus overexpressed C9orf72.  
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Generation and characterization of C9orf72 deficient mice 
Three protein isoforms of mouse C9orf72 homolog (I, 55kDa; II, 35kDa and III; 
50kDa) have been identified with isoform I (55kDa), the functional homolog of C9-L 
in humans, being the dominant form in most tissues [33, 34]. In order to investigate the 
function of C9orf72 in vivo, we generated C9orf72 deficient mice using the 
CRISPR/Cas9 system [35, 36]. Guide RNA targeted close to the start codon of the 
mouse C9orf72 isoform I and III was co-injected with the Cas9 mRNA into the 
pronuclei of fertilized eggs (Fig. 2-5a). All the offspring displayed Cas9 mediated 
cleavage and editing from non-homologous end joining mediated repair. We chose one 
founder containing a one-nucleotide deletion at the beginning of the C9orf72 open 
reading frame, resulting in a frame shift at residue 33 that produces a stop codon at 
amino acid 40 (Fig. 2-5b). Based on the splicing patterns, the one nucleotide deletion 
should cause the loss of protein products for C9orf72 isoforms I (55kDa) and III 
(50kDa), but should not affect isoform II (35kDa). Indeed, Western blot using several 
antibodies shows loss of C9orf72 isoform I protein in homozygous offspring from the 
above-mentioned founder (Fig. 2-5c, and Fig. 2-S2). We failed to detect isoform II and 
III in our Western blots with all the C9orf72 antibodies tested and thus we cannot 
determine whether these isoforms are affected by the CRISPR/Cas9 editing. While 
C9orf72 isoform I is detectable in all tissues examined, its level is highest in spleen, 
followed by kidney, brain, and heart, and much lower in the liver and muscle (Fig. 2-
5c). This expression pattern is consistent with a recent publication demonstrating the 
highest levels of C9orf72 in CD11b+ myeloid cells [22].  
Our C9orf72 deficient mice do not have any apparent growth defects (data not 
shown) but display an obvious lymph node and spleen enlargement phenotype (Fig. 2-
5d), consistent with recent reports on another two independent lines of C9orf72 
knockout mice [21, 22] . While occasional mild splenomegaly was observed in the 2 
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month old C9orf72 deficient mice, this phenotype becomes more severe with age, with 
the 4-5 month old C9orf72 deficient mouse having a spleen 2-3 times the size of its 
littermate control (Fig. 2-5d and Fig. 2-S3).  This is also seen in two of the 10 month 
old founder mice from the CRISPR mediated editing (Fig. 2-S3). The liver also shows 
slight enlargement but there are no obvious gross anatomical defects in the brain of 
C9orf72 deficient mice (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-5: Generation of C9orf72 deficient mice. a. Schematic drawing of the mouse 
homologue of C9orf72, 3110043O21RIK, and the site targeted for editing by 
CRISPR/Cas9. b.  Sequencing traces of wildtype (top) and edited (bottom) C9orf72 
from genomic PCR show a one nucleotide deletion (highlighted with yellow) near the 
(continued from previous page) Cas9 cleavage site. c. Western blot analysis of C9orf72 
protein levels in wild type  (WT) and C9orf72-/- (KO) mouse tissues with anti-C9-L 
antibodies.   d. Representative images of cervical lymph nodes and spleen from 4-5 
months old WT and C9orf72-/- mice. Scale bar=2 mm (lymph node); 1 cm (spleen).  
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Figure 2-S2: Absence of C9orf72 isoform I in the C9orf72 CRISPR targeted mice. 
a. Western blot of brain lysate from wild type (WT) or C9orf72 deficient (KO) mice 
using various C9orf72 antibodies as indicated. b. Western blot analysis of C9orf72 
protein levels in WT and KO mouse tissues with anti0C9-L antibodies.  
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Figure 2-S3: C9orf72 deficiency in mice leads to age 
dependent spleen enlargement. Representative images of 
spleen dissected form 2 month, 5 month, and 10 month old WT 
and C9orf72-/- mice are shown. Scale bar=1 cm.  
 
 
 
 
 
 
 
Hematoxylin and eosin (H&E) staining of the C9orf72 deficient spleen reveals 
enlarged germinal centers (GCs) and abundant extramedullary hematopoietic cells (Fig. 
2-6a). High magnification shows the enlarged GCs are packed with immature immune 
cells, among which plasma cells are often observed (Fig. 2-6a). Several types of 
hematopoietic cells are enriched in the red pulp (Fig. 2-6a). Immunostaining with anti-
CD68 antibodies shows macrophage accumulation or infiltration in the red pulp of the 
spleen (Fig. 2-6b), which is also seen in the peripheral regions of cervical lymph nodes 
(Fig. 2-7a) and to a lesser extent, liver of C9orf72 deficient mice at 4 months of age 
(Fig. 2-8b). In C9orf72-/- liver tissues, infiltrated immune cells were observed in both 
hepatic portal area and hepatic parenchyma (Fig. 2-8a). Surrounding by the infiltrated 
immune cells, necrotic hepatocytes are occasionally seen in C9orf72-/- liver tissues 
(Fig. 2-8a). Despite macrophage infiltration in multiple peripheral organs, microglia, 
the counterpart of macrophages in the central nervous system, do not show any obvious 
changes in number and morphology in the C9orf72 deficient mice (Fig. 2-9). 
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Figure 2-6: C9orf72 deficiency in mice results in an enlarged spleen phenotype and 
macrophage infiltration into the spleen.  
a. H&E staining of spleen tissues from 5 month old of WT or C9orf72 -/-  mouse with 
zoomed images of germinal center (GC) and red pulp (RP). (GC): Arrows indicate 
plasma cells and the arrowheads indicate immature immune cells). (RP): arrowheads 
indicate myeloid precursors; arrows indicate erythroid precursors. Scale bar=500 µm 
(100 µm in the zoomed in images for GC and RP) b. Immunostaining of 4 month old 
spleen sections (red pulp region) of WT and C9orf72-/- mice with anti-mouse CD68, 
prosaposin (PSAP), and progranulin (PGRN) antibodies. Nuclei are labelled with DAPI. 
Insert shows representative CD68+ macrophage cells. Representative pictures from 
three pairs of mice are shown. Scale bar=40 µm. c. Immunostaining of 4 month old 
spleen sections (red pulp region) of WT and C9orf72-/- mice with anti-mouse -
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(continued from previous page) Lamp1, and cathepsin D (CathD) antibodies.  Nuclei 
are labelled with DAPI. Insert shows representative cells. Representative pictures from 
three pairs of mice are shown. Scale bar=40 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-7: Increased macrophage infiltration and lysosomal proteins in the 
cervical lymph node of C9orf72 deficient mice. 
a. Immunostaining of 4 month old cervical lymph nodes sections (peripheral region) of 
WT and C9orf72-/- mice with anti-mouse CD68, prosaposin (PSAP), and progranulin 
(PGRN) antibodies. Nuclei is labelled with DAPI. Insert shows representative CD68+ 
macrophage cells. Representative pictures from three pairs of mice are shown. Scale 
bar=40 µm. b. Immunostaining of 4 month old cervical lymph nodes sections 
(peripheral region) of WT and C9orf72-/- mice with anti-mouse Lamp1, and cathepsin 
D (CathD) antibodies.  Nuclei are labelled with DAPI. Insert shows representative cells. 
Representative pictures from three pairs of mice are shown. Scale bar=40 µm. 
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Figure 2-8: C9 deficiency in mice results in macrophage infiltration and increased 
levels of lysosomal proteins in the liver.  
a. H&E staining of liver tissues from 10 month old of WT or C9orf72 -/-  mouse.  (ii) 
and (iii) are high power magnification images of the hepatic parenchyma, arrowhead 
indicates infiltrated immune cells; arrow points to necrotic hepatocyte. (v) and (vi) are 
high power magnification images of the hepatic portal area, arrowhead indicates 
infiltrated immune cells.  PV, portal vein. Scale bar: 500 µm in (i) and (iv), 100 µm in 
(ii, iii, v, vi) b. Immunostaining of 4 month old liver sections of WT and C9orf72-/- 
mice with anti-mouse CD68, prosaposin (PSAP), and progranulin (PGRN) antibodies. 
Nuclei are labelled with DAPI. Insert shows representative CD68+ macrophage cells. 
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(continued from previous page) Representative pictures from three pairs of mice are 
shown. Scale bar=40 µm. c. Immunostaining of 4 month old liver sections of WT and 
C9orf72-/- mice with anti-(continued from previous page) mouse Lamp1, and cathepsin 
D (CathD) antibodies.  Nuclei are labelled with DAPI. Insert shows representative cells. 
Representative pictures from three pairs of mice are shown. Scale bar=40 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-9: Microglia do not show any obvious abnormalities in C9orf72 deficient 
mice.  
Brain sections from 10 month old WT and C9orf72-/- mice were stained with anti-
LAMP1, Iba1 and cathepsin D antibodies. Similar results were seen with 5 month old 
C9orf72-/- mouse. Scale bar=50μm. 
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Autophagy and lysosome defects in the C9orf72 deficient mice 
Because C9orf72/SMCR8/WDR41 co-immunoprecipitates with the 
FIP200/Ulk1/ATG13/ATG101 complex, we investigated possible autophagy/lysosome 
defects in the C9orf72 deficient mice. Interestingly, Ulk1 deficiency has also been 
reported to result in splenomegaly [37].  Western blot analysis showed significantly 
increased levels of several proteins involved in the autophagy/lysosomal pathway in 
spleen and liver lysates of the 2 month old C9orf72 deficient mice compared to 
littermate controls, including LC3-I, LAMP1, and prosaposin (PSAP), even before the 
appearance of an obvious splenomegaly phenotype, suggesting that 
autophagy/lysosome defects might precede anatomical spleen abnormalities (Fig. 2-
10a, 2-10b).  Although no obvious changes in lysosomal morphology were seen in the 
C9orf72-/- macrophages, increased levels of the lysosomal proteins progranulin 
(PGRN), PSAP, LAMP1 and cathepsin D (CathD) are seen in CD68 positive 
macrophages in the lymph nodes, spleen and liver of C9orf72 deficient mice (Fig. 2-6, 
2-7, and 2-8). This might suggest that loss of C9orf72 causes a defect in the lysosome 
that requires upregulation of lysosomal proteins to compensate. Conversion of LC3-I to 
LC3-II is an indicator of autophagy initiation [38]. Although LC3-I levels are 
dramatically increased in C9orf72 deficient spleen lysates, LC3-II levels are 
significantly reduced in C9orf72 deficient spleen lysates (Fig. 2-10a, 2-10b), suggesting 
that loss of C9orf72 causes a defect in autophagy initiation. Despite these changes in 
multiple peripheral tissues, brain lysates do not show any apparent increases in 
autophagy or lysosomal proteins in the 2 month old C9orf72 deficient mice compared 
to controls (Fig. 2-10a, 2-10b).   
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Figure 2-10: C9orf72 deficiency in mice leads to increased levels of autophagy-
lysosome proteins in the spleen. a. Western blot analysis of tissue lysates from spleen, 
liver, and brain of WT and knockout mice. Representative pairs are shown. b. 
Quantification of autophagy and lysosomal protein levels in knockout mice relative to 
WT controls. Data are presented as Mean + SEM, n=3-6.  *, p < 0.05; **, p<0.01.  
 
 
 
2.4 Discussion 
The cellular function of C9orf72 has been under intensive investigation since 
hexanucleotide repeat expansion in the C9orf72 gene was shown to be the main cause 
of ALS/FTLD [8-10],  with reduced C9orf72 expression proposed as one of the disease 
mechanisms [11]. In this study, we searched for protein interactors for C9orf72 and 
identified SMCR8 and WDR41 as two binding partners of C9orf72, consistent with two 
recently published reports [26, 27].  We further demonstrated that 
C9orf72/SMCR8/WDR41 interacts with the FIP200/Ulk1/ATG13/ATG101 complex 
involved in autophagy initiation. Our data also showed that C9orf72 deficient mice 
display defects in autophagy/lysosome pathway, supporting a critical role of C9orf72 in 
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autophagy/lysosome regulation.  
Many other genes involved in membrane trafficking and autophagy have been 
associated with ALS/FTLD, including TBK1, OPTN, SQSTM1/p62, UBQLN2, 
VCP/p97 and CHMP2B [39-42]. Progranulin, the gene mutated in a vast majority of 
FTLD with ubiquitin positive TDP-43 aggregates, was recently shown to play a critical 
role in regulating lysosomal function [43, 44] and the progranulin protein was shown to 
reside in the lysosome [45, 46]. TMEM106B, a risk factor for FTLD with progranulin 
mutations, also regulates lysosomal morphology and function [47-51].  Our current 
results further support that dysfunction in the autophagy lysosome pathway is 
implicated in the disease progression of ALS/FTLD caused by C9orf72 mutations.  
C9orf72 deficiency in C. elegans and zebrafish has been shown to result in locomotion 
defects [52, 53], supporting the notion that C9orf72 haploinsufficiency could contribute 
to ALS/FTLD progression.  While neuron and glia specific C9orf72 ablation or 
intracerebral mRNA knockdown does not seem to cause motor neuron disease in mouse 
models [19, 20],  our data and recent data by others consistently demonstrate that whole 
body C9orf72 deficiency produces severe immune dysregulation in mice [21, 22]. In 
one study, lysosomal abnormalities were also observed in microglia isolated from 
C9orf72 deficient mice and in the motor cortex and spinal cord of ALS patients with 
C9orf72 mutations [22]. These findings strongly suggest that C9orf72 may regulate 
motor neuron survival through regulation of inflammatory responses by affecting 
autophagy-lysosomal function of microglia and macrophages. In contrast, our studies 
failed to detect any obvious abnormalities of microglia in our C9orf72 deficient mice 
(Fig. 9). It is possible that this may simply be due to our mice not being old enough (10 
months old) for us to detect a microglial phenotype. It is also likely that microglial 
abnormalities may become apparent in the C9orf72 deficient mice upon additional 
insults to the nervous system.   
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The physical interaction between the C9orf72/SMCR8/WDR41 complex and 
the autophagy initiation complex FIP200/Ulk1/ATG13/ATG101 (Fig. 4) suggests that 
C9orf72/SMCR8/WDR41 might regulate autophagy through the 
FIP200/Ulk1/ATG13/ATG101 complex. However, exactly how 
C9orf72/SMCR8/WDR41 regulates autophagy remains unclear. It is interesting that 
WDR41 is enriched at the Golgi, as the ER-Golgi intermediate compartment has been 
shown to serve as a key membrane source for autophagosome biogenesis [54]. One 
possibility is that C9orf72/SMCR8/WDR41 serves as a substrate and a downstream 
signaling component after Ulk1 activation. Interestingly, SMCR8 was shown to be a 
substrate for Ulk1 in a recent study [27]. This observation together with reduced 
autophagy initiation in C9or72-/- spleen tissues argues that C9orf72/SMCR8/WDR41 
functions downstream of Ulk1 activation during autophagy activation.  Autophagy 
defects in C9orf72-/- mice might trigger upregulation of autophay/lysosome genes to 
compensate for the defect. Although we failed to identify any Rab GTPases as C9orf72 
interactors in our proteomic screen, C9orf72/SMCR8/WDR41 was shown to interact 
with Rab8a and Rab39b and functions as a guanine nucleotide exchange factor (GEF) 
for Rab GTPases in a recent study [27].  However, the effect of Ulk1 phosphorylation 
on the GEF activities remains to be determined. Future endeavors are needed to further 
understand the mechanistic functions and regulations of C9orf72/SMCR8/WDR41 
complex at molecular and cellular levels. More studies are also needed to characterize 
neuronal and microglial phenotypes due to C9orf72 loss, possibly upon additional 
challenges, to explain how C9orf72 deficiency contributes to ALS/FTLD progression.  
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2.5 Conclusions 
We describe the identification of two binding partners for C9orf72: SMCR8 and 
WDR41. We demonstrated that C9orf72/SMCR8/WDR41 interacts with the 
FIP200/Ulk1/ATG13/ATG101 complex. We also generated C9orf72 deficient mice and 
showed that loss of C9orf72 leads to macrophage infiltration in multiple organs. 
Additionally, C9orf72 deficiency leads to autophagy defects and increased levels of 
many lysosomal proteins, supporting a critical role of C9orf72 in regulating 
autophagy/lysosomal pathway and inflammation in vivo. 
 
2.6 Material and methods 
DNA and Plasmids - Human C9orf72 (C9-L), WDR41 and SMCR8 cDNAs 
were from the human ORFome 8.1 library and cloned into pQCXIN, pEGFP-N1 or 
pEGFP-N2, respectively, with an N-terminal (C9orf72) or C-terminal (WDR41 and 
SMCR8) GFP tag. WDR41 and SMCR8 were also cloned into pcDNA3.1 myc his A 
(Invitrogen) to generate C-terminal myc his tagged constructs. Additionally, C9orf72 
and WDR41 were cloned into p3xFLAG-CMV7.1 (Sigma) to generate N-terminal 
FLAG tagged constructs. Myc-ATG13, FLAG-ATG101 and p3xFLAG-CMV10-
hFIP200 were obtained from Addgene (plasmid #31965, 22877 and 24300, 
respectively). 
Pharmacological Reagents and Antibodies - The following primary antibodies 
were used in this study: anti-FLAG (M2) and anti-myc (9E10) from Sigma-Aldrich, 
anti-GAPDH from Abcam (ab8245), anti-LC3B (GTX127375) and anti-C9orf72 
(GTX119776) from GeneTex, anti-Cathepsin D (sc-6486), anti-Ulk1 (sc-33182) and 
anti-C9orf72 (sc-138763) from Santa Cruz Biotechnology, anti-C9orf72 (AP12928b) 
and anti-FIP200 (17250-1-AP) from Proteintech, anti-SMCR8 from Bethyl 
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Laboratories, anti-WDR41 from Abgent, rat anti-CD68 from AbD Serotec, sheep anti-
progranulin from R&D systems and anti-mouse LAMP1 (553792) from BD 
Biosciences. Anti-mouse prosaposin antibody was generated by Pocono Rabbit Farm 
and Laboratory and was previously characterized [46]. Anti-C9orf72-long isoform [30] 
was a gift from Dr. Janice Robertson (University of Toronto); anti-GFP antibody was a 
gift from Dr. Anthony Bretscher (Cornell University); and anti-GPP130 was a gift from 
Dr. William Brown (Cornell University). The following secondary antibodies were 
used: donkey anti-mouse 800 and donkey anti-rabbit 800 from LI-COR, AlexaFluor 
donkey anti-goat 680, donkey anti-rabbit 680, donkey anti-mouse 680, and donkey anti-
rat 680 from Invitrogen, and donkey anti-mouse 568 from Biotium. Hoechst stain was 
obtained from Invitrogen. Brefeldin A (BFA), bafilomycin A1 (Bfa1) and nocodazole 
were obtained from Sigma-Aldrich and used at a final concentration of 300 μM, 50nM 
and 20mM, respectively.  
Mouse strains - C9orf72 knockout mice were produced using CRISPR/Cas9 
genome editing with a guide RNA (gRNA) targeting exon 2 of mouse gene 
3110043O21RIK. C57BL/6J x FvB/N mouse embryos were injected with gRNA and 
Cas9 mRNA at the Cornell Transgenic Core Facility. Editing was confirmed by 
sequencing PCR products from genomic DNA and loss of protein products was 
determined by Western blot of tissue lysate. Offspring from the founder containing 1bp 
deletion were used for the study except the 10 month old founder mice.  The following 
primers were used to genotype C9orf72 knockout mice: 5'- gcggctacctttgcttac -3' (WT 
forward), 5'- tggcggctacctttgcta -3 (KO forward) and 5'- tgcccaggagacacaacata -3' 
(common reverse). 
Cell Culture and DNA Transfection - HEK293T cells were maintained in 
Dulbecco’s Modified Eagle’s Medium (Cellgro) supplemented with 10% fetal bovine 
serum (Gibco) and 1% Penicillin–Streptomycin (Invitrogen) in a humidified incubator 
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at 37ºC and 5% CO2. Cells were transiently transfected with polyethyleneimine as 
described [55].   
Immunoprecipitation and protein analysis- Cells were lysed in 50 mM Tris pH 
8.0, 150 mM NaCl, 1% Triton X-100, and 0.1% deoxycholic acid with protease 
inhibitors (Roche). Lysates were incubated with GFP-Trap beads (ChromoTek) or anti-
FLAG antibody conjugated beads (Sigma-Aldrich) for 2-3 hours at 4°C. Beads were 
washed 3 times with 50 mM Tris pH 8.0, 150 mM NaCl, and 1% Triton X-100. Samples 
were denatured in 2xSDS sample buffer (4% SDS, 20% glycerol, 100 mM Tris pH 6.8, 
0.2 g/L bromophenol blue) by boiling for 3 minutes. Samples were run on 8% or 12% 
polyacrylamide gels and transferred to PVDF membranes (Millipore). Membranes were 
blocked in either Odyssey Blocking Buffer (LI-COR Biosciences) or 5% non-fat milk 
in PBS for 1 hour followed by incubation with primary antibodies overnight at 4°C. 
Membranes were washed 3 times with Tris-buffered saline with 0.1% Tween-20 
(TBST) then incubated with secondary antibody for 2 hours at room temperature. 
Membranes were washed 3 times with TBST and imaged using an Odyssey Infrared 
Imaging System (LI-COR Biosciences).  
To quantify protein levels in tissue samples, tissues were homogenized in RIPA 
buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.1% SDS and 0.1% 
deoxycholic acid) with protease inhibitors on ice and then equal volume of 2X SDS 
sample buffer was added before sonication. 50μg of each protein sample was loaded 
onto a 12% poly-acrylamide gel. Blots were analyzed by LiCor Odyssey system and 
normalized to GAPDH. 
SILAC and mass spectrometry analysis- N2a cells were grown a minimum of 
five generations in DMEM with 10% dialyzed FBS (Sigma) supplemented with either 
light (C12, N14 arginine and lysine) or heavy (C13, N15 arginine and lysine) amino 
acids. The heavy cells were transfected in two 15 cm dishes with GFP-C9orf72 
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expression constructs while the light cells were transfected with pEGFP-C1 as a control. 
Two days after transfection, cells were lysed in 50mM Tris pH8.0, 150mM NaCl, 1% 
Triton, 0.1% deoxycholic acid with protease inhibitors (Roche). The lysates were 
subject to anti-GFP immunoprecipitation using GFP-Trap beads (ChromoTek).  The 
presence of GFP and GFP-C9orf72 in immunoprecipitated samples was confirmed by 
SDS-PAGE and Krypton staining (Invitrogen). Samples were then combined and boiled 
5 minutes with 1% DTT followed by alkylation by treating samples with a final 
concentration of 28 mM iodoacetamide. Proteins were precipitated on ice for 30 minutes 
with a mixture of 50% acetone/49.9% ethanol/0.1% acetic acid. Proteins were pelleted 
and washed with this buffer, re-precipitated on ice, and dissolved in 8M urea/50 mM 
Tris pH 8.0 followed by dilution with three volumes of 50 mM Tris pH 8.0/150 mM 
NaCl. Proteins were digested overnight at 37º C with 1 μg mass-spec grade Trypsin 
(Promega). The resulting peptide samples were cleaned up for mass spectrometry by 
treatment with 10% formic acid and 10% trifluoroacetic acid (TFA) and washed twice 
with 0.1% acetic acid on pre-equilibrated Sep-Pak C18 cartridges (Waters). Samples 
were eluted with 80% acetonitrile (ACN)/0.1% acetic acid into silanized vials (National 
Scientific) and evaporated using a SpeedVac. Samples were re-dissolved in H2O with 
~1% formic acid and 70% ACN. Peptides were separated using hydrophilic interaction 
liquid chromatography (HILIC) on an Ultimate 300 LC (Dionex). Each fraction was 
evaporated with a SpeedVac and resuspended in 0.1% TFA with 0.1 pM angiotensin 
internal standard. Samples were run on a Thermo LTQ Orbitrap XL mass spectrometer 
and data analyzed using the SORCERER system (Sage-N research). 
 Hematoxylin and eosin (H&E) staining - Mouse tissues were fixed with 4% 
formaldehyde. After dehydration with 70% ethanol, tissues were embedded with 
paraffin. The tissues were sliced to 8μm. Followed by deparaffiinization with xylene 
and ethanol (100%, 95%, 80%) and rehydration with tap water, the slides were stained 
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in hematoxalin for 3 minutes, destained with acid ethanol and rinsed with tap water, and 
then stained with eosin for 30 seconds. The slides were then dehydrated with ethanol 
and xylene and mounted.  
 Immunofluorescence microscopy- HeLa cells grown on glass coverslips were 
fixed in 3.7% paraformaldehyde for 15 minutes, washed 3 times with PBS, and 
permeabilized and blocked in Odyssey Blocking Buffer with 0.05% saponin or 0.1% 
Triton for 20 minutes. Primary antibodies diluted in blocking buffer with 0.05% saponin 
were applied to the cells overnight at 4°C. Coverslips were washed 3 times with PBS. 
Secondary antibodies and Hoechst stain diluted in blocking buffer with 0.05% saponin 
were applied to the cells for 2 hours at room temperature. Coverslips were washed and 
mounted onto slides with Fluoromount G (Southern Biotech). Images were acquired on 
a CSU-X spinning disc confocal microscope (Intelligent Imaging Innovations) with an 
HQ2 CCD camera (Photometrics) using a 100x objective. 
 Mouse tissues were perfused and fixed with 4% formaldehyde. After gradient 
dehydration with 15% and 30% sucrose, tissues were embedded with OCT compound 
(Sakura Finetek USA) and sectioned with Cryotome.  For the immunostaining, tissue 
sections were permeabilized and blocked in Odyssey blocking buffer with 0.05% 
saponin for 1 hour. Primary antibodies were incubated in blocking buffer overnight at 
4ºC. Sections were washed and incubated in secondary antibodies conjugated to 
Alexaflour 488, 568, or 660 (Invitrogen). Sections were washed three more times and 
coverslips mounted onto slides with Fluoromount G (Southern Biotech). Images were 
acquired on a CSU-X spinning disc confocal microscope (Intelligent Imaging 
Innovations) with an HQ2 CCD camera (Photometrics) using a 40x objective.  
 Statistical analysis -The data were presented as mean ± SEM. Two-group 
analysis was performed using the Student’s t test. P-values <0.05 were considered 
statistically significant. 
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CHAPTER 3 
 
IDENTIFICATION OF C9ORF72-SMCR8-WDR41 COMPLEX BINDING 
PROTEINS 
 
 
3.1 ABSTRACT 
The C9orf72 gene has been found to be the leading genetic cause of ALS/FTLD. One 
proposed mechanism leading from genetic mutation to disease, is that insufficient 
protein expression contributes to development of neurodegeneration. To better 
understand the role of C9orf72 protein in disease, more needs to be known about what 
this protein normally does in the cell. To understand more about C9orf72’s protein 
network, several SILAC screen were used to identify additional protein binding partners 
of C9orf72/SMCR8/WDR41 complex. While several interactions have been validated, 
the physiological importance of these interactions remains unknown.  
3.2 INTRODUCTION 
 Intronic hexanucleotide repeat expansion in the gene C9orf72 was identified as 
a leading cause of two related neurodegenerative diseases, ALS and FTLD[1, 2]. One 
proposed model of how this mutation leads to disease is through haploinsufficiency of 
the protein product of C9orf72. In order to understand the contribution of C9orf72 
haploinsufficiency, we sought to discover the cellular function of C9orf72. By 
employing stable isotope labeling of amino acids in cell culture (SILAC) with mass 
spectrometry, we identified many potential protein interactions. We published data 
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characterizing the interaction between C9orf72, SMCR8, and WDR41. Here, I describe 
additional C9orf72 protein interactions based on mass spectrometry results and C9orf72 
domain structure predictions.  
3.3 Results  
C9orf72 SILAC-MS identifies potential protein interactions  
To discover which proteins the C9orf72-SMCR8-WDR41 complex interacts 
with, we performed several SILAC based mass spectrometry experiments. First, using 
light amino acid-labeled GFP and heavy amino acid GFP-C9orf72 overexpressed in N2a 
cells. SILAC experiments were also conducted in HEK293T cells by either co-
expressing GFP-C9orf72 with SMCR8-GFP or expressing WDR41-GFP alone. Tables 
3-1, 3-2, and 3-3 show the top hits from each of these three experiments.  
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GFP-C9orf72 in N2a cells 
orf gene Count H Count L gmean 
ALPPL2 ALPPL2 2 0 0.0121 
MMS19 MMS19 2 0 0.0207 
FSIP2 FSIP2 2 0 0.0341 
FARSA FARSA 2 0 0.0345 
ALKBH3 ALKBH3 2 0 0.0469 
WDR41 WDR41 9 1 0.0509 
C9ORF72 C9ORF72 152 53 0.0552 
SORT1 SORT1 4 0 0.0575 
FAM82A2 FAM82A2 2 0 0.059 
LAMC1 LAMC1 2 0 0.0602 
SMCR8 SMCR8 26 3 0.0641 
YME1L1 YME1L1 4 0 0.0648 
DNAJC11 DNAJC11 3 0 0.0838 
VDAC3 VDAC3 28 5 0.0978 
SSR1 SSR1 2 2 0.0987 
DERL1 DERL1 1 1 0.1111 
COL5A2 COL5A2 4 0 0.1115 
TBC1D15 TBC1D15 2 1 0.113 
RRM1 RRM1 2 1 0.1298 
AKAP8 AKAP8 2 1 0.1428 
RABIF RABIF 1 1 0.1656 
SLC25A4,SLC25A5,SLC5A6 "291-SLC25A4 15 6 0.1813 
ERGIC1 ERGIC1 4 0 0.1854 
SLC25A5 SLC25A5 31 18 0.1863 
 
Table 3-1: List of protein interactions by SILAC analysis of GFP-C9orf72 binding 
partners in N2a cells. Count H: number of peptides in the heavy fraction; Count L: 
number of peptides in the light fraction. Peptides with a gmean score <0.2 are listed. 
Bait proteins are listed in bold.  
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GFP-C9orf72 + SMCR8-GFP in HEK293T cells 
orf gene Count H Count L gmean 
PHB2 PHB2 2 0 0.0191 
TCP1 TCP1 3 0 0.0191 
SLC25A10 SLC25A10 2 0 0.0417 
"83858-ATAD3B,ATAD3A" "83858-ATAD3B 2 0 0.0722 
ATAD3A ATAD3A 4 0 0.0881 
"84617-
TUBB6,TUBB2B,TUBBA,TUBB2C" 
"84617-TUBB6 2 0 0.0932 
CIAO1 CIAO1 4 0 0.1196 
TUBB2B TUBB2B 2 0 0.1317 
HAX1 HAX1 2 0 0.1382 
"7277-
TUBA4A,TUBA1A,TUBAC,TUBA3D,
TUBA1C,TUBA8,TUA1B" 
"7277-TUBA4A 3 0 0.1679 
DNAJA1 DNAJA1 14 0 0.1706 
DNAJC11 DNAJC11 2 0 0.1816 
"3320-HSP90AA1,HSP90AA5P" "3320-HSP90AA1 3 0 0.1818 
"291-SLC25A4,SLC25A5,SLC5A6" "291-SLC25A4 4 1 0.2240 
AIFM1 AIFM1 17 1 0.2376 
DNAJA2 DNAJA2 10 0 0.2502 
MMS19 MMS19 5 0 0.2567 
SLC25A5 SLC25A5 7 2 0.2572 
RNF219 RNF219 2 0 0.2602 
SLC25A13 SLC25A13 11 0 0.2700 
C9ORF72 C9ORF72 25 10 0.2807 
"6182-MRPL12,SLC25A10" "6182-MRPL12 7 0 0.2866 
"3327-HSP90AB3P,HSP90AB1" "3327-HSP90AB3P 3 0 0.3002 
WDR41 WDR41 27 5 0.3080 
"219293-ATAD3C,ATAD3A" "219293-ATAD3C 2 0 0.3149 
TUBB4 TUBB4 4 0 0.3168 
EMD EMD 6 1 0.3449 
DPM1 DPM1 2 0 0.3636 
"83858-ATAD3B,ATAD3C,ATA3A" "83858-ATAD3B 3 0 0.3636 
FAM96B FAM96B 2 0 0.3857 
NPEPPS NPEPPS 3 0 0.3968 
SMCR8 SMCR8 71 32 0.4045 
"84617-
TUBB6,TUBB2B,TUBB,TUBB8,TUBB
2A,TUBB2C,TUB" 
"84617-TUBB6 2 0 0.4066 
"84617-
TUBB6,TUBB4Q,TUBB,TUBBP5,MC
"84617-TUBB6 5 3 0.4121 
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1R,TUBB3,TUBB2,TUBB4,TUBB8,T
UBB2A,TUBB2C,TUBB" 
BAG2 BAG2 6 2 0.4215 
TUFM TUFM 5 0 0.4263 
"10382-
TUBB4,TUBB4Q,TUBB,TUBB2C,TU
BB" 
"10382-TUBB4 2 1 0.4329 
STUB1 STUB1 5 0 0.4644 
"7277-
TUBA4A,TUBA1A,TUBAC,TUBA3D,
TUBA3E,TUBA1C,TBA4B,TUBA8,TU
BA1B" 
"7277-TUBA4A 2 1 0.4765 
"3324-
HSP90AA2,HSP90AA1,SP90AB1" 
"3324-HSP90AA2 2 0 0.5143 
"7277-
TUBA4A,TUBA1A,TUBAC,TUBA3D,
TUBA1C,TUBAL3,TBA8,TUBA1B" 
"7277-TUBA4A 3 1 0.5222 
HSP90AA1 HSP90AA1 7 0 0.5342 
KPNB1 KPNB1 2 0 0.5378 
PRKDC PRKDC 28 1 0.5398 
PSME3 PSME3 3 0 0.5488 
SLC25A3 SLC25A3 8 0 0.5494 
RPL23 RPL23 3 2 0.5590 
SLC25A11 SLC25A11 7 0 0.5619 
ATP5A1 ATP5A1 10 0 0.5721 
C1ORF57 C1ORF57 2 0 0.5750 
CCT5 CCT5 2 0 0.5892 
FAR1 FAR1 2 0 0.5892 
CCT8 CCT8 5 0 0.5947 
"478-
ATP1A3,ATP1A1,ATP1A,ATP1A2" 
"478-ATP1A3 2 0 0.6030 
"7277-
TUBA4A,TUBA1A,TUBAC,TUBA3D,
MGC16703,TUBA1CTUBA1B" 
"7277-TUBA4A 2 1 0.6045 
DNAJA3 DNAJA3 10 1 0.6120 
CHCHD3 CHCHD3 3 0 0.6205 
"292-SLC25A5,SLC25A6" "292-SLC25A5 2 1 0.6364 
SLC25A6 SLC25A6 1 1 0.6364 
"347733-TUBB2B,TUBB2A" "347733-TUBB2B 4 0 0.6441 
Table 3-2: (Previous page) List of protein interactions by SILAC analysis of GFP-
C9orf72 with SMCR8-GFP binding partners in HEK293T cells. Count H: number 
of peptides in the heavy fraction; Count L: number of peptides in the light fraction. Bait 
proteins are listed in bold. 
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GFP-WDR41 SILAC 
orf gene Count H Count L gmean 
ATAD3B ATAD3B 2 0 0.01137 
HIF1AN HIF1AN 2 0 0.01137 
FAR1 FAR1 2 0 0.02542 
XPO1 XPO1 2 0 0.02666 
STUB1 STUB1 7 0 0.02968 
WDR41 WDR41 65 20 0.04859 
IMMT IMMT 4 0 0.05018 
SLC25A5 SLC25A5 6 0 0.05259 
CCT7 CCT7 2 0 0.05272 
"291-SLC25A4,SLC25A6" "291-SLC25A4 2 0 0.05819 
ATAD3A ATAD3A 4 0 0.06326 
ARL1 ARL1 2 0 0.06432 
"219293-ATAD3C,ATAD3A" "219293-ATAD3C 3 0 0.06463 
LBR LBR 2 0 0.06795 
SLC25A11 SLC25A11 7 0 0.09676 
ATP5C1 ATP5C1 6 1 0.09794 
SLC25A22 SLC25A22 2 0 0.10906 
"83858-ATAD3B,ATAD3C,ATA3A" "83858-ATAD3B 3 0 0.1248 
DNAJA2 DNAJA2 2 0 0.12892 
SMCR8 SMCR8 9 1 0.13076 
CCT3 CCT3 5 0 0.13292 
DHCR7 DHCR7 2 0 0.13925 
PRKDC PRKDC 28 1 0.1436 
DNAJA1 DNAJA1 6 1 0.1559 
"292-SLC25A5,SLC25A6" "292-SLC25A5 2 0 0.16458 
SLC25A13 SLC25A13 7 0 0.16727 
"291-SLC25A4,SLC25A5,SLC5A6" "291-SLC25A4 2 1 0.16938 
C9ORF72 C9ORF72 6 0 0.17153 
TCP1 TCP1 4 0 0.18011 
"83858-ATAD3B,ATAD3A" "83858-ATAD3B 3 0 0.19518 
ATP5A1 ATP5A1 4 0 0.19902 
 
 
Table 3-3: (Previous page) List of protein interactions by SILAC analysis of 
WDR41-GFP binding partners in HEK293T cells. Count H: number of peptides in 
the heavy fraction; Count L: number of peptides in the light fraction. Peptides with a 
gmean score <0.2 are listed. Bait proteins are listed in bold.  
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MMS19 and Iron-Sulfur Complex Transfer Machinery  
Among the top hits identified in both the C9orf72 and C9orf72 with SMCR8 SILAC 
experiments was MMS19, a protein involved in coordinating the incorporation of iron-
sulfur (FeS) clusters into nascent FeS-containing proteins (Table 3-1, Table 3-2, Figure 
3-1A) [3, 4]. Interestingly, a previously reported mass spectrometry analysis of MMS19 
binding proteins also identified SMCR8, WDR41, and C9orf72 as potential hits [4]. To 
test this interaction, I co-immunoprecipitated (Co-IP) GFP alone, GFP-C9orf72, or 
SMCR8-GFP co-expressed MMS19-V5 in HEK293T cells and found that MMS19 was 
present after C9orf72 and SMCR8 Co-IP but not GFP alone (Figure 3-1B). MMS19 
contains several HEAT (Huntingtin, Elongation factor 3, protein phosphatase 2A, and 
mTOR) domains, several of which are clustered at the C-terminal end of MMS19 and 
are critical for interacting with apo-proteins about to receive a FeS cluster whereas the 
rest of the protein coordinates the binding of several proteins involved in FeS transfer 
(Figure 3-1A) [5]. To test which domain of MMS19 interacts with C9orf72, I made two 
truncations. One lacks the HEAT repeat domain (ΔHEAT) and another with only the 
HEAT repeat domain (HRD). Co-IP of FLAG-tagged MMS19 constructs for GFP-
C9orf72 showed that the ΔHEAT construct had the strongest interaction with C9orf72 
(Figure 3-1C). Finally, to test if components of the C9orf72 complex interacted with 
other proteins involved in FeS transfer, I conducted a Co-IP for GFP-C9orf72, SMCR8-
GFP, or WDR41-GFP in the presence of four additional FeS proteins: NARFL, CIAO1, 
ANT2, and FAM96B (Figure 3-1D) [4, 6]. Despite one SILAC screen identifying 
CIAO1 and FAM96B as potential binding partners to C9orf72 and SMCR8 (Table 3-
2), the interaction could not be verified by Co-IP in HEK293T cells (Figure 3-1D).  
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Figure 3-1: C9orf72 complex interaction with MMS19. a. Schematic of the cytosolic 
iron-sulfur assembly pathway and schematic of MMS19 domain structure. b. Western 
blot results from Co-IP of overexpressed GFP, GFP-C9orf72, or SMCR8-GFP with 
MMS19-V5 in HEK293T cells. c. Western blot of Co-IP with overexpressed FLAG-
tagged full length, HEAT, or ΔHEAT Repeat Domain (HRD) MMS19 with GFP-
C9orf72. d. Western blot of Co-IP between GFP-C9orf72, SMCR8-GFP, or WDR41-
GFP and NARFL-myc, CIAO1-myc, ANT2-myc, and FAM96B-myc.  
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TRiC/Chaperonin Complex 
Another protein complex that was identified by SILAC in multiple experiments was the 
TRiC (T-Complex protein-1 Ring Complex) or CCT (Chaperonin Containing T-
Complex Protein-1) complex, an eight-subunit complex that aids in the proper folding 
of many substrates, including tubulin, actin, and many WD-repeat containing 
proteins[7, 8]. Furthermore, mutations in the TRiC complex have been associated with 
sensory neuropathy and genetic disruption of the TRiC complex was shown to delay 
autophagy initiation by disrupting the actin cytoskeleton[9, 10]. Since WDR41 is 
predicted to be almost entirely WD-repeats, TRiC may act as a chaperone for WDR41, 
thus affecting the stability of the C9or72 complex[11, 12]. The C9orf72 complex might 
also directly interact with TRiC to regulate its function. However, no binding was 
observed when overexpressed GFP-C9orf72, SMCR8-GFP, and WDR41-GFP were 
coexpressed and pulled down to identify whether TCP-1α, a component of the TRiC 
complex, is also pulled down (Figure 3-2A). Additionally, no binding was observed 
with TCP-1β or TCP-1δ in the presence of overexpressed GFP-C9orf72 and SMCR8-
GFP (Figure 3-2B). These data suggest that the C9orf72 complex and TRiC complex 
do not directly interact. To test whether loss of C9orf72 complex components had any 
effect on TRiC complex, TCP-1α was blotted in C9orf72, WDR41, or SMCR8 knockout 
MEF cell lysates (Figure 3-2C). While C9orf72 and WDR41 knockouts did not seem to 
have any effect, loss of SMCR8 increased the protein levels of TCP-1α (Figure 3-2C).  
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Figure 3-2: C9orf72 does not interact with the Tri/Chaperonin complex. a. Western 
blot for the IP of overexpressed GFP, GFP-C9orf72, SMCR8-GFP, or WDR41-GFP 
and blotted for endogenous TCP-1α. b. Western blot of Co-IP with overexpressed GFP-
C9orf72 and SMCR8-GFP for endogenous TCP-1β or TCP-1δ. c. Endogenous TCP-1α 
in 3 sets of either WT, C9orf72-/-, WDR41-/-, or SMCR8-/- mouse embryonic 
fibroblasts.  
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Tubulin 
Another protein that was found in multiple SILAC experiments was Tubulin (Table 3-
2). While tubulin can be a common contaminant in mass spectrometry experiments due 
to its abundance, overexpressed GFP-C9orf72 and SMCR8-GFP appear to specifically 
pull down endogenous α-tubulin from HEK293T lysates (Figure 3-3A).  Furthermore, 
this interaction is modulated by nutrient starvation, as FLAG-C9orf72 can better pull 
down tubulin under amino acid starvation conditions (Figure 3-3B) [13]. Finally, to test 
whether microtubule structure is disrupted upon C9orf72 knockout, primary cultured 
macrophages were stained for α-tubulin after nutrient starvation (Figure 3-3C).  
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Figure 3-3: C9orf72 interaction with tubulin. a. Western blot for the IP of 
overexpressed GFP, GFP-C9orf72, SMCR8-GFP, or WDR41-GFP and blotted for 
endogenous α-tubulin. b. Western blot for Co-IP of overexpressed FLAG-C9orf72 for 
endogenous α-tubulin with or without 60 minutes of amino acid starvation. c. WT and 
C9orf72-/- MEF cells stained fixed and stained for α-tubulin after 60 minutes of amino 
acid starvation.  
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Small GTPases 
An early characterization of C9orf72 and SMCR8 by structural prediction 
suggested that they both contain DENN (Differentially Expressed in Normal and 
Neoplastic) domains (Figure 3-4A), which are commonly found in Rab GTPase GEFs 
(Guanine Exchange Factors) [14] [15]. Despite no sequence homology to the canonical 
DENN domains, C9orf72 and SMCR8 were predicted to contain this domain by 
comparing the predicted secondary structures to that of non-canonical DENN domain 
containing protein Folliculin (FLCN), which actually acts as a GAP (GTPase Activating 
Protein) to activate RagC/D by promoting the GDP-bound form of RagC/D [14] [16]. 
This prediction has led many labs to test C9orf72 and SMCR8 interaction with various 
Rab GTPases. To date, other labs have proposed that C9orf72 or C9orf72 with SMCR8 
interact with Rab1, Rab5, Rab7, Rab8A, and Rab38B [17] [18, 19]. Despite not 
identifying any Rab GTPases in our SILAC screens, we have also tested a panel of 
available Rab GTPases for Co-IP with C9orf72, SMCR8, and WDR41. To test for Rab 
GTPase interactions, GFP-tagged Rabs were pulled down in the presence of FLAG-
C9orf72, SMCR8-myc, and WDR41-myc (Figure 3-4B). While no Rab Co-IPs 
demonstrated clear binding to SMCR8 or WDR41, C9orf72 bound to several Rabs, 
including Rab5, Rab7, Rab35, and Rab39A.  
Since Rab39B was reported as a target of C9orf72 and SMCR8 GEF activity, I 
further tested the interaction with the related Rab39A by overexpressing combinations 
of GFP-tagged C9orf72, SMCR8, and WDR41 with myc-tagged Rab39A (Figure 3-
5A). Rab39A bound to C9orf72 alone, but bound more strongly to C9orf72 with 
SMCR8 present while the presence of WDR41 had little effect (Figure 3-5A). To further 
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characterize this interaction, the interaction of wild type (WT) Rab39A with C9orf72 
was compared to constitutively active Rab39A (QL; mimicking GTP-bound, active 
state) or the dominant negative Rab39A (SN; mimicking GDP/nucleotide free state). 
C9orf72 and SMCR8 bound most strongly to the WT and constitutively active Rab39A 
(Figure 3-5B).  
Rab5 and Rab7 binding was also previously reported, though with less 
characterization [17]. In addition to binding WT Rab5 and Rab7, the constitutively 
active Rab5 shows increased binding to  C9orf72 and SMCR8, whereas the dominant 
negative, inactive Rab7 shows the same binding as WT Rab7 (Figure 3-4C).  
 The only GTPase identified by SILAC analysis was Arl1, found in the WDR41-
GFP screen (Table 3-3). This interaction was also tested by Co-IP using overexpressed 
GFP-C9orf72, SMCR8-myc, and FLAG-Arl1 in HEK293T cells (Figure 3-6A). 
However, no binding was observed between Arl1 and C9orf72 with SMCR8. As 
C9orf72 and SMCR8 were predicted to contain DENN domains based on the structure 
of FLCN, a Rag GTPase interacting protein, the interaction with Rag GTPases was also 
tested[16]. Overexpressed GFP-C9orf72 and SMCR8-myc were pulled down from 
HEK293T lysates and endogenous RagA and RagC were blotted (Figure 3-6B). As with 
Arl1, no interaction between RagA or RagC and C9orf72 was observed.  
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Figure 3-4: C9orf72 is predicted to interact with Rab GTPases through a DENN 
domain. a. C9orf72 sequence and schematic of predicted domains. Upstream DENN 
(uDENN) is shown in red, DENN domain in yellow, and dDENN in gray. b. Western 
blot of Co-IP pulling down GFP-tagged Rab GTPases for FLAG-C9orf72, SMCR8-
myc, and WDR41-myc.  
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Figure 3-5: C9orf72 interaction with Rab39A, Rab5, and Rab7. a. Western blot for 
Co-IP from overexpressed GFP-C9orf72, SMCR8-GFP, and/or WDR41-GFP for 
Rab39A-myc in HEK293T cells. b. Western blot for Co-IP with GFP or GFP-tagged 
Rab39A WT, constitutively active (QL), or dominant negative (SN) for FLAG-C9orf72, 
SMCR8-myc, and WDR41-myc in HEK293T cells. c. Western blot for Co-IP with GFP 
or GFP-tagged Rab5 WT (5 WT), Rab5 constitutively active (5 QL), Rab7 WT (7 WT), 
or Rab7 dominant negative (7 SN) for FLAG-C9orf72, SMCR8-myc, or WDR41-myc 
in HEK293T cells.  
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Figure 3-6: C9orf72 does not interact with other small GTPase candidates. a. 
Western blot for Co-IP between overexpressed GFP or GFP-C9orf72 with SMCR8-myc 
and FLAG-Arl1 in HEK293T cells. b. Western blot of IP of GFP-C9orf72 and SMCR8-
myc for endogenous RagA and RagC using CHAPS-based immunoprecipitation buffer.   
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3.4 CONCLUSIONS AND DISCUSSION  
We found that C9orf72 has many potential binding partners beyond SMCR8 and 
WDR41, with which it forms a tight complex. Here, we report interactions with 
MMS19, tubulin, Rab5, Rab7, Rab35, and Rab39A. However, beyond verifying these 
binding partners through Co-IP, we don’t yet know the physiological implications of 
these interactions or the consequences of loss of the C9orf72 complex on these proteins.   
 The interaction with MMS19 suggests that C9orf72, SMCR8, and/or WDR41 
may either play a role in FeS cluster dynamics or be an FeS cluster containing protein. 
That C9orf72 binds to the ΔHEAT MMS19 construct suggests that C9orf72 plays a 
regulatory role unlike proteins that bind the HRD of MMS19 to accept an FeS cluster. 
However, C9orf72, SMCR8, and WDR41 did not bind to additional FeS cluster 
transport proteins (NARFL, CIAO1, FAM96B, or ANT2) despite CAIO1 and FAM96B 
also appearing in the SILAC screen results (Table 3-2). Future experiments will need to 
test whether C9orf72 or SMCR8 contain an FeS cluster. One way to test this is to treat 
cells with an iron chelator such as desferrioxamine and observe endogenous protein 
levels of C9orf72 and SMCR8. Most proteins that contain an FeS cluster require it for 
stability. Purification of these proteins for structural studies or spectroscopic studies can 
also indicate whether or not they contain an FeS cluster. Given that we see disruption 
of mTOR signaling (see chapter 4) and that MMS19 has no reported role in the mTOR 
pathway, the physiological importance of this interaction remains in question.  
 The TRiC/chaperonin complex did not show binding to C9orf72, SMCR8, or 
WDR41 by Co-IP even though nearly all of the eight subunit have appeared in the 
SILAC screens. This may be in part due to the nature of the TRiC complex and the 
sensitivity of SILAC. The TRiC complex was previously reported to help fold many 
classes of proteins, including proteins containing WD repeat domains, as WDR41 
does[8]. With WDR41 overexpressed, TRiC is likely bound to nascent WDR41 peptides 
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that are being overproduced by transient expression. As SILAC is highly sensitive, it 
may be able to pick up a low level of interaction that is too low to detect by Western 
blotting. Additionally, just as loss of WDR41 or SMCR8 decreases C9orf72 stability, 
WDR41 is likely destabilized by the loss C9orf72 or SMCR8 and may result in 
increased TRiC expression to keep WDR41 properly folded, as reported with expression 
of aggregating poly-Q proteins[20]. While this interaction may provide insight into the 
synthesis and stability of the C9orf72-SMCR8, WDR41 complex, it is unlikely to be 
relevant to the main function of the C9orf72 complex.  
 The interaction between C9orf72 and tubulin was verified by Co-IP and also 
seems to be regulated by nutrient availability. Microtubules are known to undergo 
remodeling upon starvation and autophagy induction[13]. This process of remodeling 
requires additional protein interactions that are often regulated by post-translational 
modifications (PTM) of tubulin, such as phosphorylation and acetylation. As we see 
increased binding between C9orf72 and tubulin upon amino acid starvation, the 
interaction may be dependent on one such PTM. Using antibodies specific to modified 
tubulin may indicate whether one of these PTM is mediating the interaction. 
Furthermore, loss of C9orf72 in primary macrophages shows stronger staining for 
microtubules after nutrient starvation. This may indicate the microtubules are not 
remodeling properly. Watching microtubule dynamics in knockout cells will be crucial 
to understanding what effect, if any, loss of the C9orf72 complex has on microtubules. 
Additionally, cell fractionation for free tubulin dimers and microtubules will be a more 
quantitative measure of whether loss of C9orf72 is effecting microtubule dynamics.  
 Finally, the interaction with multiple Rab GTPases continues a major question 
in the field studying C9orf72. The prediction that C9orf72 and SMCR8 contain DENN 
domains have led many groups to test the interaction with various Rab GTPases[17-19]. 
However, no two groups have reported interaction with the same Rab. Furthermore, we 
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have not found any Rabs in our SILAC screens, suggesting that if there is binding to a 
Rab, the interaction may be very transient. Our panel of Rabs only include Rab GTPases 
that we had ready access to and do not include other potential Rabs or classes of small 
GTPases. Nonetheless, we did identify several Rab GTPases that showed binding to the 
C9orf72 complex. Rab5 and Rab7 had previously been reported to bind C9orf72, but 
the physiological implications of this interaction were not described. Rab5 and Rab7 
function in the endocytic pathway and play a role in endosome/lysosome maturation.  
 Rab39B, a paralogue of Rab39A, was also reported to bind C9orf72 and 
SMCR8. This report also showed GEF activity of C9orf72 and SMCR8 acting on 
Rab39B and Rab8A[19]. Oddly, we did not see binding to either of these proteins, even 
in the same conditions described by the earlier report.  
 We also observed binding to Rab35, which is involved in the endocytic pathway. 
Interestingly, constitutively active Rab35 can active AKT signaling, upstream of mTOR 
and autophagy[21, 22]. More detailed experiments will be needed to address which, if 
any, of these interactions are physiologically important.  
 
3.5 MATERIALS AND METHODS 
SILAC and mass spectrometry analysis- N2a or HEK293T cells were grown a 
minimum of five generations in DMEM with 10% dialyzed FBS (Sigma) supplemented 
with either light (C12, N14 arginine and lysine) or heavy (C13, N15 arginine and lysine) 
amino acids. The heavy cells were transfected in two 15 cm dishes with GFP-C9orf72, 
GFP-C9orf72 with SMCR8-GFP, or WDR41-GFP expression constructs while the light 
cells were transfected with pEGFP-C1 as a control. Two days after transfection, cells 
were lysed in 50mM Tris pH8.0, 150mM NaCl, 1% Triton, 0.1% deoxycholic acid with 
protease inhibitors (Roche). The lysates were subject to anti-GFP immunoprecipitation 
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using GFP-Trap beads (ChromoTek).  The presence of GFP and GFP-C9orf72, 
SMCR8-GFP, and WDR41-GFP in immunoprecipitated samples was confirmed by 
SDS-PAGE and Krypton staining (Invitrogen). Samples were then combined and boiled 
5 minutes with 1% DTT followed by alkylation by treating samples with a final 
concentration of 28 mM iodoacetamide. Proteins were precipitated on ice for 30 minutes 
with a mixture of 50% acetone/49.9% ethanol/0.1% acetic acid. Proteins were pelleted 
and washed with this buffer, re-precipitated on ice, and dissolved in 8M urea/50 mM 
Tris pH 8.0 followed by dilution with three volumes of 50 mM Tris pH 8.0/150 mM 
NaCl. Proteins were digested overnight at 37º C with 1 μg mass-spec grade Trypsin 
(Promega). The resulting peptide samples were cleaned up for mass spectrometry by 
treatment with 10% formic acid and 10% trifluoroacetic acid (TFA) and washed twice 
with 0.1% acetic acid on pre-equilibrated Sep-Pak C18 cartridges (Waters). Samples 
were eluted with 80% acetonitrile (ACN)/0.1% acetic acid into silanized vials (National 
Scientific) and evaporated using a SpeedVac. Samples were re-dissolved in H2O with 
~1% formic acid and 70% ACN. Peptides were separated using hydrophilic interaction 
liquid chromatography (HILIC) on an Ultimate 300 LC (Dionex). Each fraction was 
evaporated with a SpeedVac and resuspended in 0.1% TFA with 0.1 pM angiotensin 
internal standard. Samples were run on a Thermo LTQ Orbitrap XL mass spectrometer 
and data analyzed using the SORCERER system (Sage-N research). 
DNA and Plasmids - Human C9orf72 , WDR41 and SMCR8 cDNAs were from 
the human ORFome 8.1 library and cloned into pQCXIN, pEGFP-N1 or pEGFP-N2, 
respectively, with an N-terminal (C9orf72) or C-terminal (WDR41 and SMCR8) GFP 
tag. WDR41 and SMCR8 were also cloned into pcDNA3.1 myc his A (Invitrogen) to 
generate C-terminal myc his tagged constructs. Additionally, C9orf72 and WDR41 
were cloned into p3xFLAG-CMV7.1 (Sigma) to generate N-terminal FLAG tagged 
constructs. MMS19 was obtained from the DNAUS Plasmid Repository and cloned into 
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pcDNA3.1 V5 (Invitrogen) or p3xFLAG-CMV7.1 (Sigma). MMS19 truncations were 
based on the following amino acids positions: ΔHEAT (1-855) and HRD (856-1030) 
and were cloned into p3xFLAG-CMV7.1. NARFL, ANT2, CIAO1, and FAM96B were 
obtained from the human ORFome 8.1 library and cloned into pcDNA3.1 myc his A 
(Invitrogen) to generate C-terminally tagged constructs. Rab4, Rab5, Rab7, Rab9, and 
Rab11 in pEGFP vectors were received from Dr. William Brown (Cornell University). 
Rab8, Rab27A, Rab35, Rab5 Q67L, and Rab7 S22N in pEGFP vectors were received 
from Dr. Anthony Bretscher (Cornell University). Rab14, Rab23, Rab32, Rab39A, and 
Rab39B were obtained from the human ORFome 8.1 library and cloned into pEGFP. 
Rab39A S22N, Rab39A Q72L, Rab39B S22N, and Rab39B Q68L were created by site-
directed mutagenesis and confirmed by sequencing. Arl1 was obtained from the human 
ORFome 8.1 library and cloned into p3xFLAG-CMV7.1.  
Pharmacological Reagents and Antibodies - The following primary antibodies 
were used in this study: anti-FLAG (M2) and anti-myc (9E10) from Sigma-Aldrich, 
anti-GAPDH from Abcam (ab8245), anti-V5 from Invitrogen, anti-TCP-1α (91A) from 
Santa Cruz Biotechnology, anti-Tubulin from Proteintech Group, RagA (D8B5) and 
RagC (D31G9) from Cell Signaling Technology, and anti-GFP antibody was a gift from 
Dr. Anthony Bretscher (Cornell University). The following secondary antibodies were 
used: donkey anti-mouse 800 and donkey anti-rabbit 800 from LI-COR, AlexaFluor 
donkey anti-goat 680, donkey anti-rabbit 680, donkey anti-mouse 680, and donkey anti-
rat 680 from Invitrogen, and donkey anti-mouse 568 from Biotium. Hoechst stain was 
obtained from Invitrogen.  
Immunoprecipitation and protein analysis- Cells were lysed in 50 mM Tris pH 
8.0, 150 mM NaCl, 1% Triton X-100, and 0.1% deoxycholic acid with protease 
inhibitors (Roche) or in 0.3% CHAPS, 10mM β-glycerol phosphate, 10mM 
pyrophosphate, 40mM Hepes pH7.4, 2.5mM MegCl2, and EDTA-free protease inhibitor 
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(Roche). Lysates were incubated with GFP-Trap beads (ChromoTek) or anti-FLAG 
antibody conjugated beads (Sigma-Aldrich) for 2-3 hours at 4°C. Beads were washed 3 
times with 50 mM Tris pH 8.0, 150 mM NaCl, and 1% Triton X-100 or in 0.3% CHAPS, 
10mM β-glycerol phosphate, 10mM pyrophosphate, 40mM Hepes pH7.4, 2.5mM 
MegCl2, 150mM NaCl . Samples were denatured in 2xSDS sample buffer (4% SDS, 
20% glycerol, 100 mM Tris pH 6.8, 0.2 g/L bromophenol blue) by boiling for 3 minutes. 
Samples were run on 12% polyacrylamide gels and transferred to PVDF membranes 
(Millipore). Membranes were blocked in either Odyssey Blocking Buffer (LI-COR 
Biosciences) or 5% non-fat milk in PBS for 1 hour followed by incubation with primary 
antibodies overnight at 4°C. Membranes were washed 3 times with Tris-buffered saline 
with 0.1% Tween-20 (TBST) then incubated with secondary antibody for 2 hours at 
room temperature. Membranes were washed 3 times with TBST and imaged using an 
Odyssey Infrared Imaging System (LI-COR Biosciences).  
Cell Culture and DNA Transfection - HEK293T, N2a, and MEF cells were 
maintained in Dulbecco’s Modified Eagle’s Medium (Cellgro) supplemented with 10% 
fetal bovine serum (Gibco) and 1% Penicillin–Streptomycin (Invitrogen) in a 
humidified incubator at 37ºC and 5% CO2. Cells were transiently transfected with 
polyethyleneimine.  MEF cells were collected from P0 mouse pups by removing the 
head and limbs, then dissecting the skin from each pup. The resulting tissue was minced 
using a razor blade, then suspended in 3 ml trypsin for 30 minutes with pipetting every 
10 minutes to mechanically break up the tissues. Trypsin was then quenched with 7 mL 
of growth media. The total 10 mL volume was then plated in 10cm plates and allowed 
to grow to 90% confluence before splitting for use. Bone marrow derived macrophages 
were collected by harvesting mice 2 months of age or older, dissecting femurs, and 
flushing each femur with DMEM to collect the bone marrow. Cells were triturated by 
pipetting then passed through a 70 μm filter. Cells were plated in growth media 
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containing 20% L929 cell conditioned media and used for experiments after 7 days of 
differentiation.  
 Immunofluorescence microscopy- MEF cells grown on glass coverslips were 
fixed in 3.7% paraformaldehyde for 10 minutes, washed 3 times with PBS, and 
permeabilized and blocked in Odyssey Blocking Buffer with 0.05% saponin. Primary 
antibodies diluted in blocking buffer with 0.05% saponin were applied to the cells 
overnight at 4°C. Coverslips were washed 3 times with PBS. Secondary antibodies 
diluted in blocking buffer with 0.05% saponin were applied to the cells for 2 hours at 
room temperature. Coverslips were washed and mounted onto slides with Fluoromount 
G (Southern Biotech). Images were acquired on a CSU-X spinning disc confocal 
microscope (Intelligent Imaging Innovations) with an HQ2 CCD camera (Photometrics) 
using a 63x objective. 
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CHAPTER 4 
 
LOSS OF C9ORF72 BINDING PARTNER SMCR8 DISRUPTS MTOR 
SIGNALING BY INCREASING AKT ACTIVITY 
 
4.1 Abstract 
Intronic hexanucleatide repeat expansions in the gene C9orf72 are associated with 
ALS/FTLD. To better understand whether C9orf72 haploinsufficiency was involved in 
disease onset, we set out to elucidate the cellular function of C9orf72. We previously 
found that C9orf72 binds to SMCR8 and WDR41 and may be involved in regulating 
autophagy. Furthermore, loss of C9orf72 in mice disrupts the immune system, causing 
autoimmune-like symptoms. Here, we report that loss of SMCR8, but not WDR41, 
causes a similar phenotype to C9orf72 knockout and that loss of SMCR8 causes a 
decrease in lysosomal protein levels due to increased activity of mTOR and AKT. Our 
results provide additional insight into how the C9orf72-SMCR8-WDR41 complex may 
function.  
 
4.2 Introduction 
 C9orf72, a protein associated with ALS/FTLD, forms a complex with two 
additional proteins: WDR41 and SMCR8[1-6]. While C9orf72 has gained attention over 
the past few years, the uncharacterized SMCR8 and WDR41 have received less 
attention and their functions, like C9orf72, remains elusive.  
 Recent publications confirmed that C9orf72 binds SMCR8, and that these 
proteins bind to Ulk1[1, 2, 4, 5, 7]. SMCR8 has also been reported to alter both 
autophagy and mTOR activity, though reports disagree with exactly how this disruption 
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occurs. [3, 6, 7]. These models propose that C9orf72 and SMCR8 are effectors of Rab1A 
to help recruit the Ulk1 complex to sites of autophagy initiation while another model 
suggests that SMCR8 and C9orf72 function at the lysosome and alter mTOR activity 
due to disruption of normal lysosome activity [3, 7]. Another model suggests that 
C9orf72 and SMCR8 are GEFs for Rab8A and Rab39B and promote autophagy through 
the direct activation of these Rabs [1].  
 To study the C9orf72-SMCR8-WDR41 complex in more mechanistic detail and 
resolve the discrepancies between recent studies, we generated SMCR8 and WDR41 
knockout mice in addition to our C9orf72 knockout mice and characterized the cellular 
phenotypes of primary knockout cells. We found, like the C9orf72-/- mice, SMCR8-/- 
causes abnormal immune response. Moreover, loss of SMCR8 increased mTOR and 
AKT phosphorylation, suggesting that growth factor sensing may be disrupted. Our data 
suggests that the C9orf72-SMCR8-WDR41 complex may act upstream of AKT to 
regulate mTOR signaling and that C9orf72 and SMCR8 act together to regulate immune 
response, whereas WDR41 is dispensable for this function.  
 
4.3 Results 
To study the function of the C9orf72-SMCR8-WDR41 complex, we created 
SMCR8 and WDR41 knockout mice using CRIPR-Cas9. From the founder mice, we 
choose a mouse line with a 128 base pair (bp) deletion just after the start codon of 
SMCR8, resulting in a frame shift and early stop codon after 22 amino acids (Figure 4-
1A). For the WDR41 mice, we choose a line that contained a 122bp deletion that 
encompassed the start codon (Figure 4-1B). Since C9orf72-/- mice show splenomegaly 
by 4 months of age, we checked whether WDR41-/- or SMCR8-/- mice exhibited a 
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similar phenotype. SMCR8 mice had significantly enlarged spleens by 4 months of age 
(Figure 4-2A) while the WDR41-/- mice had no spleen enlargement at this age or up to 
12 months old (Figure 4-2B and data not shown). When WDR41-/- and C9orf72-/- were 
crossed to produce double knockout (DKO) mice, there was a slight reduction in 
spleen/body size compared to C9orf72-/- alone in 9 month old mice, suggesting that 
loss of WDR41 may rescue some phenotypes of the C9orf72-/- mice (Figure4-2B).  
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Figure 4-1: CRISPR-Cas9 genome editing produces SMCR8 and WDR41 
knockout mice. a. SMCR8 gene schematic and sequence showing start codon 
(underlined), the gRNA target sequence (red), and deleted region (highlighted in 
yellow). The DNA sequencing trace is shown below and indicates the location of the 
deletion (highlighted in yellow). b. WDR41 gene schematic, sequence, and trace labeled 
as in a.  
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Figure 4-2: Loss of SMCR8, but not WDR41, mimics C9orf72 deletion. A. 
Representative spleens taken from WT, SMCR8 Heterozygous deletion (+/-) and 
SMCR8 knockout (-/-) mice. Quantification of spleen weight at 4 months of age (n=3). 
B. Representative spleens from WT of WDR41-/- at 6 months of age and quantification 
of spleen weight of WT, C9orf72+/-, C9orf72-/-, WDR41-/- and DKO (n=12-14). ** 
p<0.01; *** p<0.001; **** p<0.0001. Scale bar = 1cm.  
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Since these three proteins form a complex and help to stabilize one another, we 
checked the protein levels of C9orf72 in WDR41 and SMCR8 knockout tissues and 
MEFs. Loss of either WDR41 (Figure 4-3A) or SMCR8 (Figure 4-3B) led to a decrease 
in C9orf72 levels. Furthermore, loss of C9orf72, but not WDR41, decreased the protein 
levels of SMCR8 in MEFs (Figure 4-3C). Finally, looking at mouse tissues, loss of 
SMCR8 led to decreased C9orf72 protein levels in all analyzed tissues (Figure 4-3D). 
WDR41 protein levels were not included due to the absence of quality WDR41 
antibodies available. These results confirm that each component of the C9orf72 
complex is important for its stability.  
Our previous work, as well as the work of other groups, have suggested that the 
C9orf72 complex plays a role in autophagy or mTOR signaling. To test the hypothesis 
that mTOR activity may be changed, I check the ratio of phosphorylated mTOR at 
Serine 2448 to total mTOR and found that SMCR8-/- MEF had a greater ratio of p-
mTOR than WT (Figure4-4A). If mTOR is more active in SMCR8-/- cells, mTOR 
should have increased localization at lysosomes. SMCR8-/- MEFs stained for mTOR 
and a lysosome marker, LAMP1, show increased mTOR signal at the lysosome (Figure 
4-4B). Since mTOR is phosphorylated at this site downstream of Pi3K/AKT signaling, 
we also looked at the phosphorylation of AKT at Ser473 and Thr308. Ser473 of AKT 
is phosphorylated by PDK1 while Thr308 is phosphorylated by mTORC2. Both of these 
signaling events are induced by the presence of growth factors. We found that the ratio 
of p-Ser473 AKT to total AKT is increased, whereas p-Thr308 AKT has less change 
from WT cells (Figure 4-4A).   
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Figure 4-3: Loss of C9orf72 complex components destabilizes the entire complex. 
a. WDR41-/- spleen tissue and MEF cell lysate blotted for C9orf72 and GAPDH. 
Quantification of C9orf72 levels normalized to GAPDH on right (n=3). b. SMCR8-/- 
spleen tissue and MEF cell lysate blotted for C9orf72 and GAPDH. Quantification of 
C9orf72 levels normalized to GAPDH on right (n=3). c. Verification of SMCR8 
antibody and C9orf72-/- and WDR41-/- MEF cell lysate blotted for SMCR8 and actin. 
Quantification of SMCR8 levels normalized to actin on right (n=3). d. Tissue lysates 
from WT and SMCR8-/- mice blotted for C9orf72 and actin.  
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Figure 4-4: Loss of SMCR8 increases AKT and mTOR activity. a. Western blot of 
WT and SMCR8-/- MEF lysates blotted for phosphor-Ser2448 mTOR (p-mTOR), total 
mTOR, p-AKT (T308), p-AKT (S473), and total AKT. Quantification on the right 
(n=3). b. WT and SMCR8-/- MEF stained for mTOR and LAMP1. 
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4.4 Discussion 
 Despite many recent publications relating to the function of C9orf72 and 
SMCR8, the physiological role of this complex remains unclear. Many reports suggest 
that autophagy and mTOR are disrupted by loss of C9orf72 or SMCR8, however they 
disagree on the precise contribution of C9orf72 and SMCR8 to these pathways. Our 
data has suggested that C9orf72 and SMCR8 may function upstream of mTOR and 
AKT, thus affecting downstream signaling events that initiate autophagy and control 
TFEB localization. However, as our group and others have reported direct interaction 
with the Ulk1 complex, these data may indicate that C9orf72, SMCR8, and WDR41 
play multiple roles in the cell, both directly affecting autophagy through the interaction 
with Ulk1 and upstream by affecting growth factor signaling through the PI3K/AKT 
pathway. Interestingly, we see binding of C9orf72 and SMCR8 to Rab35, which has 
been reported to modulate the activity of AKT through its direct interaction with PI3K 
[8, 9]. More experiments will be needed to address the hypothesis that C9orf72 and 
SMCR8 act on Rab35 to modulate the activity of AKT. Additionally, it remains unclear 
why loss of C9orf72 and SMCR8 produce a similar phenotype in mice while WDR41 
does not. This may be due to the relative decreases in C9orf72 and SMCR8 in WDR41 
knockout tissues. While C9orf72 is greatly reduced, SMCR8 is not. This would suggest 
that the level of SMCR8 may be more important than C9orf72. Many of these 
hypothesis will need to be further addressed through cellular and molecular approached 
to fully appreciate the function of the C9orf72-SMCR8-WDR41 complex. 
 
4.5 Materials and methods  
Mouse strains – SMCR8 and WDR41 knockout mice were produced using 
CRISPR/Cas9 genome editing with a guide RNA (gRNA) targeting exon 1 of mouse 
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gene SMCR8 or WDR41. C57BL/6J x FvB/N mouse embryos were injected with gRNA 
and Cas9 mRNA at the Cornell Transgenic Core Facility. Editing was confirmed by 
sequencing PCR products from genomic DNA. Offspring from the founder containing 
128bp deletion in SMCR8 or 122bp deletion in WDR41 were used for the study.  The 
following primers were used to genotype SMCR8 knockout mice: 
5'- GCTGGTGACCTAGCTTCAGG -3' (forward) and 5'- 
ACCGACATAATCCGCAAAGA -3' (reverse). The following primers were used to 
genotype WDR41 knockout mice: 5'- CGAGACTTCTGTTTTCCCGCT -3' (forward) 
and 5'- TGTTGTGTGGCACATGAAGT -3' (reverse). 
Antibodies - The following primary antibodies were used in this study: anti-
GAPDH from Abcam (ab8245), mTOR (7C10) and p-mTOR (D9C2) from Cell 
Signaling Technology, anti-Actin from Lifetein, anti-SMCR8 from Bethyl, anti-AKT, 
anti-phosphoSer473 AKT, and anti-phsophoT308 AKT from Santa Crus 
Biotechnology, LAMP1 from BD Biosciences, and anti-C9orf72 long was a gift from 
Dr. Janice Robertson (University of Toronto). The following secondary antibodies were 
used: donkey anti-mouse 800 and donkey anti-rabbit 800 from LI-COR, AlexaFluor 
donkey anti-rabbit 680, donkey anti-mouse 680, and donkey anti-rabbit 488 from 
Invitrogen, donkey anti-rat568 from Jackson ImmunoResearch.  
Protein analysis- To quantify protein levels in tissue samples, tissues were 
homogenized in RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% Triton X-100, 
0.1% SDS and 0.1% deoxycholic acid) with protease and phosphatase inhibitors on ice 
and then equal volume of 2X SDS sample buffer was added before sonication. 50μg of 
each protein sample was loaded onto a 12% poly-acrylamide gel. Blots were analyzed 
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by LiCor Odyssey system and normalized to GAPDH or actin. 
Cell Culture and DNA Transfection - MEF cells were maintained in Dulbecco’s 
Modified Eagle’s Medium (Cellgro) supplemented with 10% fetal bovine serum 
(Gibco) and 1% Penicillin–Streptomycin (Invitrogen) in a humidified incubator at 37ºC 
and 5% CO2. Cells were transiently transfected with polyethyleneimine.  MEF cells 
were collected from P0 mouse pups by removing the head and limbs, then dissecting 
the skin from each pup. The resulting tissue was minced using a razor blade, then 
suspended in 3 ml trypsin for 30 minutes with pipetting every 10 minutes to 
mechanically break up the tissues. Trypsin was then quenched with 7 mL of growth 
media. The total 10 mL volume was then plated in 10cm plates and allowed to grow to 
90% confluence before splitting for use.  
 Immunofluorescence microscopy- MEF cells grown on glass coverslips were 
fixed in 3.7% paraformaldehyde for 10 minutes, washed 3 times with PBS, and 
permeabilized and blocked in Odyssey Blocking Buffer with 0.05% saponin. Primary 
antibodies diluted in blocking buffer with 0.05% saponin were applied to the cells 
overnight at 4°C. Coverslips were washed 3 times with PBS. Secondary antibodies 
diluted in blocking buffer with 0.05% saponin were applied to the cells for 2 hours at 
room temperature. Coverslips were washed and mounted onto slides with Fluoromount 
G (Southern Biotech). Images were acquired on a CSU-X spinning disc confocal 
microscope (Intelligent Imaging Innovations) with an HQ2 CCD camera (Photometrics) 
using a 100x objective. 
 Statistical analysis -The data were presented as mean ± SEM. Two-group 
analysis was performed using the Student’s t test. P-values <0.05 were considered 
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statistically significant. Graphpad Prism was used for statistical analysis.  
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CHAPTER 5 
 
CONCLUDING REMARKS AND FUTURE RESEARCH DIRECTIONS 
 
 
In early 2012, C9orf72 was reported to be associated with Amyotrophic Lateral 
Sclerosis (ALS) and FrontoTemporal Labor Degeneration (FTLD) [1-3]. Since these 
initial reports, many groups have studied the mechanisms that lead from an intronic 
hexanucleotide repeat expansion to ALS/FTLD. Observing the molecular pathology, 
groups found that long, repetitive RNA are transcribed in both the sense and anti-sense 
direction which can sequester RNA-binding proteins and disrupt nucleocytoplasmic 
translocation[2, 4-8]. Additionally, these repetitive transcripts are translated by Repeat-
Associated Non-atg (RAN) translation into multiple dipeptide repeats[9-11]. These 
dipeptide repeats form persistent aggregates and are also thought to disrupt 
nucleocytoplasmic transport. Early reports also suggested that translation of the normal 
protein C9orf72 is suppressed by hypermethylation of the repeat expansion leading to 
haploinsufficiency of this uncharacterized protein[2, 12-14]. With these three potential 
mechanisms of disease in mind, we set out to understand the function the protein product 
of C9orf72 and uncover its contribution to ALS/FTLD.  
 Over the past five years, multiple groups have found that introducing RNA 
repeats or dipeptide repeats into cellular, fly, and mouse models is sufficient to cause 
neurodegeneration[15-19]. However, loss of C9orf72 in mouse models produces only 
mild impairment of motor and cognitive function[20-24]. These models have led groups 
to believe that the toxic gain of function from the RNA repeats and dipeptide repeats 
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are responsible for the onset of disease, though loss of C9orf72 protein may contribute 
to pathology in conjunction with gain of toxicity.  
 Yet, the function of C9orf72 remains unclear. Several groups have proposed 
functions for C9orf72, but few of these reports fully agree with one another. During my 
studies in Dr. Hu’s lab, we have found that C9orf72 binds to two previously 
uncharacterized proteins, SMCR8 and WDR41. Together, these proteins are able to 
further interact with the autophagy initiation complex composed of ULK1, FIP200, 
ATG13, and ATG101. We also reported that loss of C9orf72 in mice leads to 
splenomegaly and mis-regulation of the immune system, but had no obvious effect on 
the brain or microglia[24].  How C9orf72 depletion leads to this immune phenotype is 
still unclear, though several groups have independently reported the phenomenon[22-
24]. To further characterize this immune phenotype, I had begun a collaborative project 
with Dr. Cynthia Leifer’s lab to test whether Toll-Like Receptor signaling was impaired 
in C9orf72 knockout. Our preliminary results suggested that there may be a defect, but 
follow up experiments were inconsistent.  
Additionally, we reported that WDR41 localization is enriched at the Golgi. This 
is an interesting observation, as we do not see clear evidence that C9orf72 and SMCR8 
also are enriched at the Golgi, despite their strong interaction with WDR41. One 
possibility is that the overexpressed protein does not localize properly, with either 
C9orf72 and SMCR8’s cytoplasmic localization or WDR41’s Golgi localization an 
artifact of overexpression. However, WDR41 overexpression is sufficient to cause 
vesicle formation and bind to these unidentified vesicles, as I show in appendix II. For 
future studies, either quality antibodies or endogenous tagging of these proteins using 
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CRISPR-mediated editing will be useful in determining reliable localization of C9orf72, 
SMCR8, and WDR41 at physiological conditions. To better understand the WDR41-
induced vesicles, overexpressing WDR41 in either C9orf72-/- or SMCR8-/- cells will 
help discern whether WDR41 acts with the C9orf72 complex or independently to cause 
this phenomenon. Characterizing this event may suggest potential Rab GTPases as 
binding partners, as many Rabs are involved in vesicle formation.  
 In trying to determine the function of C9orf72, we conducted several SILAC 
experiments to identify binding partners that might place C9orf72 in a specific cellular 
pathway. I tested several candidates including MMS19, the TRiC complex, tubulin, and 
many small GTPases. MMS19 contains many HEAT domains, which are usually 
involved in mediating multiple protein-protein interactions. Since these domains 
coordinate the multiple interactions, they may be binding nonspecifically to C9orf72 
and SMCR8 in the overexpressed conditions. To show that this is a physiological 
interaction, the binding should be shown at the endogenous level. Furthermore, if 
C9orf72 is regulating MMS19, rather than being a substrate, loss of C9orf72 should 
disrupt iron-sulfur (FeS) cluster assembly. Most notably, many DNA repair proteins use 
FeS clusters to carry out enzymatic functions[25, 26]. If they do not receive an FeS cells 
will become more susceptible to DNA damage, which may be a good indication of 
disrupted FeS assembly in C9orf72 or SMCR8 knockout.  
I did not observe any binding with another top candidate, the TRiC complex. If 
there is binding that was too weak to detect by Co-IP, it may be for the proper folding 
of WDR41, as the TRiC complex is known to help for WD repeat proteins[27]. 
Nonetheless, I do not think that C9orf72 has any functional role with the TRiC complex. 
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On the other hand, the interaction between C9orf72 and tubulin is interesting. Originally 
disregarded as a contaminant, I verified the interaction by Co-IP and found that the 
interaction was dependent on nutrient status. Furthermore, microtubules in C9orf72-/- 
macrophages seemed to be more stable, showing stronger signal and possibly longer 
polymers. Confirming the interaction at the endogenous level, as well as following 
microtubule dynamics in knockout cells will be an important next step. Discovering 
what regulates this interaction in a nutrient-dependent manner will also provide insight.  
 The possible interaction with several small GTPases adds to a continued 
assumption that C9orf72 and SMCR8 actually do contain a DENN domain and act as a 
guanine exchange factor to activate a small GTPase. With only structural predictions of 
a DENN domain and no consensus on which GTPase is the target of C9orf72 and 
SMCR8, the field needs compelling data that includes GEF activity assays and 
connection to demonstrated phenotypes, such as changes in mTOR signaling and 
autophagy induction. Along these lines, our results show that Rab35 binds C9orf72 and 
SMCR8. Rab35 has been reported to affect AKT signaling through direct interaction 
with PI3K[28] and constitutively active Rab35 increased AKT phosphorylation and 
activity[29]. As I show in Chapter 4, our data suggests that AKT phosphorylation is 
increased. If C9orf72 and SMCR8 act as a GTPase Activating Protein (GAP), then loss 
of SMCR8 would increase the active, GTP-bound Rab35 and mimic the constitutively 
active results. Although DENN domains usually act as GEFs, the DENN domain-
containing protein Folliculin acts as a GAP[30]. Since Folliculin was used to predict the 
DENN domain in C9orf72 and SMCR8, there is a possibility that these proteins act as 
GAPs rather than the canonical GEFs. Folliculin was also shown to have GEF activity 
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towards Rab35 in vitro[31]. These data together support the hypothesis that C9orf72 
and SMCR8 act on Rab35. Future studies of this interaction should include binding 
affinity to the constitutively active (Q67L) and dominant negative (S22N) mutants of 
Rab35, colocalization of Rab35 with the C9orf72 complex, and GTPase activity assays 
using purified proteins.  
 In chapter 4, I provide evidence that loss of SMCR8, but not WDR41, results in 
a similar immune phenotype as C9orf72-/- mice. Furthermore, loss of any component 
of the C9orf72 complex decreased the stability of the remaining proteins, reinforcing 
the hypothesis that these proteins function as a complex. The stability of WDR41 in 
C9orf72-/- and SMCR8-/- still needs to be assessed when a quality antibody is available. 
Finally, loss of SMCR8 results in altered mTOR activity, seen by increased 
phosphorylation and increased localization of mTOR to lysosomes under basal 
conditions. We found that upstream of mTOR, AKT phosphorylation is also increased, 
indicating that AKT also has higher activity. How the C9orf72 complex is able to 
regulate AKT is still unclear, though Rab35 activity is a potential candidate as 
mentioned earlier (Figure 5-1). 
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Figure 5-1: Summary of C9orf72/SMCR8/WDR41 functions. The C9orf72 complex 
directly interacts with the Ulk1 complex as well as several Rab GTPases. Loss of 
SMCR8 results in mis-regulated autophagy/lysosomal signaling. Loss of either C9orf72 
or SMCR8 results in immune activation in vivo.  
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 Here, I have presented data that begins to elucidate the function of C9orf72 at a 
cellular and organismal level. My data has found that C9orf72 binds SMCR8 and 
WDR41 to form a protein complex. Each component of this complex is important for 
the stability of the entire complex, as loss of any one of these three protein causes a 
decrease of other complex components. SMCR8 protein is almost completely lost in the 
C9orf72-/- cells and tissues, but has little change in the WDR41-/-, whereas C9orf72 
levels are decreased by loss of either SMCR8 or WDR41. I have also shown that the 
C9orf72 complex interacts with the Ulk1-FIP200 complex, as well as the cytoskeletal 
component tubulin, and several Rab GTPases. Furthermore, I provide evidence that 
mTOR phosphorylation and localization is mis-regulated and that AKT phosphorylation 
is also altered in SMCR8-/- cells. Finally, I have created knockout mice for C9orf72, 
SMCR8, and WDR41 using CRISPR-Cas9 and preliminarily characterized the 
phenotypes that these mice exhibit. Altogether, my data support a role for the C9orf72-
SMCR8-WDR41 complex in regulating the AKT-mTOR signaling pathway and 
maintaining proper immune regulation.  
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APPENDIX I 
 
THE INTERACTION BETWEEN PROGRANULIN AND PROSAPOSIN IS 
MEDIATED BY GRANULINS AND THE LINKER REGION BETWEEN 
SAPOSIN B AND C  
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A1.1 Abstract  
The frontotemporal lobar degeneration (FTLD) protein progranulin (PGRN) is essential 
for proper lysosomal function. PGRN localizes in the lysosomal compartment within 
the cell. Prosaposin (PSAP), the precursor of lysosomal saposin activators (saposin A, 
B, C, D), physically interacts with PGRN. Previously we have shown that PGRN and 
PSAP facilitate each other’s lysosomal trafficking. Here we report that the interaction 
between PSAP and PGRN requires the linker region of saposin B and C (BC linker). 
PSAP protein with the BC linker mutated fails to interact with PGRN and target PGRN 
to lysosomes in the biosynthetic and endocytic pathways. On the other hand, PGRN 
interacts with PSAP through multiple granulin motifs.  Granulin D and E bind to PSAP 
with similar affinity as full length PGRN. In summary, our data shows that the BC linker 
of PSAP interacts with multiple granulin motifs in PGRN. 
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A1.2 Introduction 
Frontotemporal lobar degeneration (FTLD) is the most prevalent early onset 
dementia after Alzheimer’s disease (AD) and accounts for 20-25% of pre-senile 
dementias [1]. A large subset of FTLD cases has characteristic ubiquitin-positive 
inclusions comprised of the protein TDP-43 (FTLD-TDP) [2, 3]. Haploinsufficiency of 
progranulin (PGRN) due to mutations in the granulin (GRN) gene is one of the major 
causes of FTLD-TDP [4-6].  PGRN is an evolutionarily conserved glycoprotein of 7.5 
granulin repeats with multiple functions in the nervous system, including neuronal 
survival and regulating microglia mediated inflammation [7-9]. Recent studies, 
however, have supported a surprising role of PGRN in the lysosome. While PGRN 
haploinsufficiency causes FTLD, total loss of PGRN in humans results in neuronal 
ceroid lipofuscinosis (NCL) [10, 11], a lysosomal storage disease [12, 13]. Furthermore, 
PGRN is transcriptionally co-regulated with a number of essential lysosomal genes by 
the transcriptional factor TFEB [14]. Finally, within the cell, PGRN localizes to the 
lysosomal compartment.  The VPS10 family trafficking receptor sortilin is highly 
expressed in neurons and interacts with the C-terminus of PGRN to mediate PGRN 
lysosomal targeting [15, 16]. More recently, PGRN was also shown to directly bind 
another lysosomal protein, prosaposin (PSAP), and get a “piggyback” ride to lysosomes 
through the PSAP receptors M6PR and LRP1 [17].  In fibroblasts which do not express 
sortilin, PGRN lysosomal trafficking is totally dependent on PSAP [17].  The interaction 
between PGRN and PSAP was further confirmed by a large family-based genome-wide 
association study (GWAS) study, in which polymorphisms in PSAP were shown to 
affect plasma PGRN levels [18]. 
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 PSAP is the precursor of lysosomal saposin activators (saposin A, B, C and D) 
essential for glycosphingolipid degradation, and mutations in the saposin motifs are 
known to cause several distinct lysosomal storage diseases [19-21].  The physical 
interaction of PGRN and PSAP not only facilitates PGRN lysosomal trafficking but also 
PSAP trafficking, as we have recently shown that PGRN bridges the interaction between 
PSAP and sortilin to facilitate PSAP uptake and lysosomal delivery in neurons [22]. 
Furthermore, PGRN haploinsufficiency in FTLD patients impairs PSAP lysosomal 
trafficking and decreases neuronal saposin level [22]. Thus PGRN and PSAP facilitate 
each other’s lysosomal trafficking, and PGRN-PSAP interaction is important for 
maintaining proper lysosomal function in the aged brain.  In addition, both PGRN and 
PSAP are also secreted and both have been reported to have neurotrophic functions [7-
9, 19-21, 23]. The interaction of PGRN and PSAP in the extracellular space might also 
regulate their neurotrophic properties. Thus given the importance of PGRN-PSAP 
interaction and relevance to FTLD, we decided to map domains involved in PGRN-
PSAP binding.   Here we report that PSAP interacts with PGRN through granulin motifs 
in PGRN and the linker region between saposin B and C (BC linker) in PSAP.  
 
A1.3 Results 
PSAP interacts with granulin motifs in PGRN 
To determine the binding site for PSAP in PGRN, we made a series of deletion 
constructs of individual granulin (Grn) motifs (Fig. AI-1A).  While deletion of both Grn 
D and Grn E motifs results in a great decrease of the interaction between PGRN and 
PSAP, further deletion of other granulin motifs only slightly weaken the interaction, 
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suggesting that Grn D and Grn E are the main binding site for PSAP in PGRN (Fig. 1B). 
To further confirm that PSAP interacts with granulins, we tested the interaction between 
PSAP and individual granulins tagged with alkaline phosphatase (AP) or GFP. Among 
the AP-tagged granulins with decent expression, granulin A, B, D and E 
coimmunoprecipitate with PSAP, but Grn D and E exhibited the strongest binding 
towards PSAP (Fig. AI-1C). Grn G, on the other hand, does not show any detectable 
binding to PSAP (Fig. AI-1C). Similarly, with GFP-tagged granulins, granulins D and 
E showed the strongest interaction followed by granulin B (Fig. AI-1D). Taken together, 
these results suggest that PGRN binds to PSAP through multiple granulin motifs with 
highest affinity to Grn D and E. 
To determine the relative affinity for the PSAP and PGRN/Grn binding, we 
anchored PSAP to the cell surface by fusing it to the transmembrane domain of PDGF 
receptor and measured the binding affinity using an alkaline phosphatase (AP) based 
cell surface binding assay (Hu et al., 2010). AP-Grn D and AP-Grn-E bind to PDGFR 
fused PSAP on the cell surface with a Kd around 20nM, similar to that of full length 
PGRN (Fig. A1-2), confirming that these two granulin motifs are the main binding sites 
for PSAP in PGRN.  
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Figure AI-1: Domain structure of human PGRN (aa 1-593). (B) HEK293T cells 
were co-transfected with FLAG tagged PGRN truncation constructs and untagged 
human PSAP as indicated. Cells were lysed two days after transfection and the lysates 
were immunoprecipitated with anti-FLAG antibodies. The IP products were analyzed 
by Western blot using anti-FLAG and anti-PSAP antibodies (RRID:AB_2172462). (C) 
Conditioned medium from HEK293T expressing different AP-fusion proteins were 
incubated with FLAG beads only or FLAG beads with FLAG-PSAP recombinant 
proteins. The amount of AP proteins co-immunoprecipitated with FLAG-PSAP was 
analyzed by Western blot. (D) Conditioned medium from HEK293T expressing 
different GFP-fusion proteins were mixed with 1μg purified recombinant FLAG-PSAP. 
Immunoprecipitations were then performed with anti-GFP antibodies and the IP 
products were analyzed by Western blot. (Conducted by FH and PS) 
 
Figure AI-2: Granulin D and E bind to PSAP with similar affinity as full length 
PGRN. (A) Conditioned medium containing AP, AP-PGRN, AP-Grn D, or AP-Grn E 
were incubated with COS-7 cells transfected with PSAP fused to PDGFR. Cells were 
fixed and AP binding was visualized with AP substrates. Scale bar=100μm. (B) AP–
PGRN binding to PSAP-PDGFR expressing COS-7 cells measured as a function of AP–
PGRN concentration. (C-E) Scatchard plot of AP-PGRN (C), AP-GRN D (D) or AP-
GRN E (E) binding to PSAP-PDGFR expressing COS-7 cells. KD, mean ± sem, n = 4. 
(Conducted by XZ)  
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PSAP interacts with PGRN through the linker region between saposin B and C  
To map the binding site for PGRN in PSAP, we created a series of PSAP deletion 
constructs and tested their interaction with PGRN.  While deletion of saposin D (ABC) 
has no effect on the PSAP-PGRN interaction, further deletion of saposin C and the 
linker region between saposin B and C (AB) results in loss of the PGRN-PSAP 
interaction (Fig. AI-3A).  The construct containing saposin B, the BC linker, and saposin 
C (BC), binds to PGRN as strong as full-length PSAP (Fig. AI-3B). This suggests that 
PGRN interacts with saposin C or the linker region between B and C. However, saposin 
C itself is not sufficient to interact with PGRN (Fig. AI-3B). Addition of the BC linker 
region to saposin C (L+C) allows full binding to PGRN despite very weak expression, 
suggesting that the BC linker region is the binding site for PGRN in PSAP (Fig. AI-3B). 
This is further supported with purified recombinant saposin proteins from bacteria. 
None of the recombinant saposin domains interact with PGRN, but fusion of the BC 
linker region with saposin C allows strong binding to PGRN (Fig. AI-3C). To determine 
if the BC linker alone is able to bind with PGRN, we fused either saposin B plus BC 
linker or BC linker alone with the transmembrane and cytoplasmic domains of LAMP1 
(TcLAMP1). The co-immunoprecipitation result shows that FLAG-tagged BC linker-
TcLAMP1 was able to co-immunoprecipitate PGRN as efficiently as FLAG tagged 
saposin B plus BC linker and FLAG tagged full-length PSAP (Fig. AI-3D), suggesting 
that the BC linker alone is sufficient for PGRN binding.  
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Figure AI-3: PSAP interacts with PGRN through the BC linker. (A) HEK293T cells 
were co-transfected with FLAG tagged PGRN and full length his-PSAP or PSAP 
truncation mutants as indicated. Cells were lysed two days after transfection and the 
lysates were immunoprecipitated with anti-FLAG antibodies. The IP products were 
analyzed by Western blot using anti-FLAG and anti-PSAP antibodies 
(RRID:AB_2172462). (B) HEK293T cells were co-transfected with untagged PGRN 
and FLAG tagged PSAP fragments as indicated. Cells were lysed two days after 
transfection and the lysates were immunoprecipitated with anti-FLAG antibodies. (C) 
Recombinant Gst- or his-sumo tagged saposins purified from bacteria were incubated 
with FLAG beads only or FLAG beads with FLAG-PGRN recombinant proteins. The 
amount of saposin co-immunoprecipitated with FLAG-PGRN was analyzed by Western 
blot. (D) HEK293T cells were co-transfected with untagged PGRN and FLAG tagged 
full-length PSAP, full-length LAMP1, saposin B with BC linker fused with 
transmembrane and cytoplasmic domain of LAMP1 (Tc-LAMP1) and BC linker fused 
with Tc-LAMP1 as indicated. Cells were lysed two days after transfection and the 
lysates were immunoprecipitated with anti-FLAG antibodies and immunoblotted with 
anti-PGRN and anti-FLAG antibodies. (Conducted by PS and XZ). 
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To further prove that the BC linker is the binding site for PGRN in PSAP, we 
generated a PSAP mutant construct in which the BC linker is replaced by the linker 
between saposin C and D (CD linker) (Fig. AI-4A). This replacement totally abolished 
the binding between PSAP and PGRN in the co-immunoprecipitation (Fig. AI-4A) and 
cell surface binding assays (Fig. AI-4B), further supporting that the BC linker is 
required for binding between PSAP and PGRN. 
PSAP mutant that fails to bind to PGRN cannot deliver PGRN to lysosomes 
Previously, we showed that PSAP mediates sortilin-independent delivery of 
PGRN into lysosomes (Zhou et al., 2015).  In fact, since sortilin is not expressed in 
fibroblasts, lysosomal trafficking of PGRN is totally abolished in PSAP deficient 
fibroblasts (Zhou et al., 2015). We predicted that the PSAP mutant with its PGRN 
binding site mutated cannot facilitate PGRN lysosomal trafficking. Indeed, the PSAP 
mutant with the BC linker replaced by the CD linker fails to rescue the PGRN trafficking 
defect in PSAP deficient fibroblasts, although lysosomal trafficking of the PSAP mutant 
itself is not impaired (Fig. AI-5A, AI-5B). PSAP also facilitates lysosomal delivery of 
PGRN from the extracellular space. However, this is also abolished by mutation of the 
BC linker region of PSAP. While recombinant wild type PSAP facilitates neuronal 
uptake and lysosomal delivery of recombinant PGRN protein lacking the sortilin 
binding site (Zheng et al., 2011), the PSAP mutant with the BC linker replaced fails to 
do so (Fig. AI-5C, AI-5D, AI-5E). 
 
 
 
 129 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure AI-4: PSAP mutant with the BC linker replaced failed to interact with 
PGRN. (A) HEK293T cells were co-transfected with FLAG tagged wild type (WT) or 
mutant (mut) PSAP and untagged human PGRN as indicated. Media was collected and 
cells were lysed three days after transfection. The lysates and media were separately 
immunoprecipitated with anti-FLAG antibodies. (B) Conditioned medium containing 
AP or AP-PGRN were incubated with COS-7 cells transfected with WT or mutant PSAP 
fused to PDGFR. Cells were fixed and AP binding were visualized with AP substrates. 
Scale bar=100μm  (Conducted by XZ and LS)  
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Figure AI-5: PSAP mutants fail to deliver PGRN to lysosomes. (A) PSAP-/- mouse 
fibroblasts were infected with lentivirus expressing WT or mutant PSAP with the BC 
linker replaced by CD linker. Cells were fixed and stained with rabbit anti-human 
saposin B, sheep anti-mouse PGRN and rat anti-LAMP1 antibodies. Scale bar=10 μm. 
(B) The colocalization of PGRN with lysosomal marker LAMP1 in (A) were quantified 
using Image J. n=3, ***, p<0.001. (C) Grn-/- cortical neurons were incubated with C-
terminally FLAG his tagged human PGRN which does not bind to sortilin (5ug/ml) 
together with recombinant WT PSAP or mutant PSAP with the BC linker replaced by 
CD linker (5ug/ml). 12 hours later, cells were fixed and stained with rabbit anti-human 
saposin B, goat anti-human PGRN and rat anti- LAMP1 antibodies. Scale bar=10 μm. 
(D, E) The endocytosed PGRN (D) and PSAP (E) for the experiment in (C) were 
quantified by using Image J. n=3; ns, no significance; ***, p<0.001. One way ANOVA. 
(Conducted by XZ).  
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A1.4 Discussion 
Our previous studies have shown that PGRN and PSAP form a complex both 
intracellularly and extracellularly and facilitate each other’s lysosomal delivery (Zhou 
et al., 2015; Zhou et al., 2017b). Since both PGRN and PSAP are essential for proper 
lysosomal function and loss of function in either gene causes lysosomal storage 
diseases, more studies on the interaction of PGRN and PSAP will help us develop 
strategies to enhance the function of PGRN and PSAP. This will be of therapeutic 
interest for FTLD, since haploinsufficiency of PGRN is a leading cause of FTLD and 
impaired PSAP lysosomal trafficking is observed in FTLD patients with GRN mutations 
(Zhou et al., 2017b). Future studies to design or screen small molecules to enhance the 
binding affinity between these two proteins might be therapeutic interest.  Thus it is 
important for us to understand the molecular mechanisms involved in the physical 
interaction between PGRN and PSAP.   
In agreement with our previous finding that saposins do not bind to PGRN (Zhou 
et al., 2015), here we show that PGRN interacts with the linker between saposin B and 
C domain through multiple granulin motifs. Granulin D and E bind to PSAP with similar 
affinity as full length PGRN. How the BC linker region interacts with granulin motifs 
is still unclear and structural studies will be useful to further understand this interaction. 
We have failed to further narrow down the binding site in the 37 amino acid BC linker 
to a shorter peptide (data not shown).   But most likely PSAP-PGRN binding involves 
an interaction between a peptide (BC linker) and a folded domain (granulins).  
PSAP is known to undergo processing into saposins during its trafficking to 
lysosomes (Matsuda et al., 2007; O'Brien and Kishimoto, 1991; Qi and Grabowski, 
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2001). Additionally, PGRN is hypothesized to be processed into granulin peptides in 
the lysosome (Cenik et al., 2012). Both PGRN and PSAP have been shown to interact 
with cathepsin D (Beel et al., 2017; Gopalakrishnan et al., 2004; Laurent-Matha et al., 
2002; Zhou et al., 2017a) and cathepsin D is known to cleave PSAP during trafficking 
(Gopalakrishnan et al., 2004). Thus it is possible that binding of PGRN to the BC linker 
region of PSAP will affect the kinetics of PSAP, and maybe also PGRN processing.  
Since granulin peptides, especially granulin D and E, bind to PSAP with the similar 
affinity as full length PGRN, granulins might interact with full length PSAP or its 
processing intermediates with BC linker still attached. The relative rates of PGRN and 
PSAP processing during trafficking and in the lysosome might determine the interaction 
modes between the final products and processing intermediates of these two proteins. 
Further studies on these aspects of PGRN-PSAP biology will allow a better 
understanding on how these two proteins interact and regulate each other’s functions 
and help develop therapeutic means to enhance their activities.   
 
A1.5 Materials ad Methods 
Antibodies- The following antibodies were used in this study: mouse anti-FLAG (M2) 
from Sigma (RRID:AB_439685), rabbit anti-human PSAP antibodies from Proteintech 
Group (RRID:AB_2172462), goat anti-human PGRN (RRID:AB_2114489), and sheep 
anti-mouse PGRN (RRID:AB_2114504) from R&D systems, rat anti-mouse LAMP1 
(1D4B) from BD Biosciences  (RRID:AB_2134499). Rabbit anti-human saposin B 
antibodies (Leonova et al., 1996) is a gift from Dr. Xiaoyang Qi (University of 
Cincinnati School of Medicine, Cincinnati, OH).  
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DNA and Plasmids - Full length human PSAP and PGRN expression constructs were 
previously described (Zhou et al., 2015). FLAG tagged PGRN and PSAP truncation 
constructs were generated by cloning the PGRN and PSAP fragments into the 
pSectag2B vector (Invitrogen) with an N-terminal FLAG tag. GST-saposin constructs 
and his Sumo saposin constructs were generated by cloning saposin and linker regions 
into pGEX6p-1 and pET his Sumo vector, respectively. AP-granulin constructs were 
generated by cloning granulins into pAP5 vector (Genhunter). GFP-granulins were 
generated by inserting GFP and granulin sequences into pSectag2B vector after the 
signal sequence.  PSAP mutant with the BC linker (amino acid sequence: 
VKEMPMQTLVPAKVASKNVIPALELVEPIKKHEVPAK) replaced by CD linker 
was generated from hPSAP construct by PCR using following primers (hSap B 3: 
5PhosCTCATCACAGAACCCAACC and CD linker hSap C 5: 5Phos 
ACGCGGCTGCCTGCACTGACCGTTCACGTGACTCAGCCAAAGGACGGTTCT
GATGTTTACTGTGAGGTG). His tagged and lentiviral human WT PSAP, human 
mutant PSAP with the BC linker replaced by CD linker, and human PGRN constructs 
were generated by cloning corresponding genes into pSectag2B vector (Invitrogen) and 
into pCDH-puro vector (System bio), respectively. To generate fusion construct of 
PSAP with the platelet derived growth factor receptor (PDGFR) transmembrane 
domain, full-length WT and mutant PSAP with the BC linker replaced by CD linker 
were cloned into the pDisplay vector (Invitrogen). Rat FLAG-RFP-LAMP1 was 
obtained from Addgene. FLAG tagged SapB-BC linker-TcLAMP1 or BC linker-
TcLAMP1 were generated by clone rat transmembrane and cytosolic domains of 
LAMP1 (Tc) into FLAG-SapB-BC linker and FLAG-BC linker constructs (with stop 
 134 
codon removed) using XhoI and PmeI sites.  
Cell Culture- HEK293T (RRID:CVCL_0063, from ATCC), COS-7 
(RRID:CVCL_0224, from ATCC) and WT and PSAP-/- fibroblast cells (derived from 
Psap-/- mice (RRID:IMSR_JAX:002792)) were maintained in Dulbecco’s Modified 
Eagle’s medium (Cellgro) supplemented with 10% fetal bovine serum (Gibco) and 1% 
Penicillin–Streptomycin (Invitrogen) in a humidified incubator at 37ºC and 5% CO2. 
Cells were transiently transfected with polyethyleneimine (PEI) as described (Vancha 
et al., 2004).  Psap-/- fibroblasts were infected with lentivirus expressing WT or mutant 
PSAP.  
Primary cortical neurons were isolated from P0-P1 pups from Grn-/- mice (Jackson 
laboratories, RRID:IMSR_JAX:013175) using a modified protocol (Beaudoin et al., 
2012).  Briefly, cortices were rapidly dissected from the brain in 2 mL HBSS 
supplemented with B27 (ThermoFisher Scientific catalog#17504044) and 0.5 mM L-
glutamine (ThermoFisher Scientific catalog#25030024) at 4°C. Meninges were 
removed before digestion with papain (Worthington LS003119, 2mg/ml in HBSS) and 
DNaseI (1mg/ml in HBSS, Sigma) for 12 minutes at 37°C. Tissues were then 
dissociated using fire polished glass pipettes. Cells were spun down and resuspended in 
Neuroplex medium (Gemini) plus B27 and plated onto poly-lysine (Sigma) coated 
dishes.  
Protein preparation and Western blot analysis- Purification of recombinant his-human 
WT PSAP, mutant PSAP with BC linker replaced with CD linker, and his-human PGRN 
proteins, co-immunoprecipitation (IP) assays and Western blots were performed as 
previously described (Zhou et al., 2015).  Gst and his-sumo saposin fusion proteins were 
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purified using Gst or cobalt beads, respectively, from Origami™ B(DE3) strain 
(Novagen) after IPTG induction. 
Cell surface binding assay and binding- AP binding assays were done as previously 
described (Hu et al., 2010). Briefly, conditioned medium with AP or AP-
PGRN/Granulins generated from HEK293T cells were incubated with pDisplay-PSAP-
transfected COS-7 cells or for 2 h at room temperature before fixation and heat 
inactivation of endogenous AP at 65°C overnight. Bound AP to the primary cortical 
neurons was measured using NIH image software. Followed by measuring the intensity 
of bound AP signal, the saturation binding curves and scatchard plots were generated, 
and binding KD were calculated by using GraphPad Prism 5.0 software. 
Immunofluorescence staining- Immunofluorescence staining was performed as 
previously described (Zhou et al., 2015). Briefly the cells were fixed with 4% 
paraformaldehyde and permeabilized and blocked with blocking buffer (0.05% saponin, 
3% BSA in PBS). The cells were incubated with primary antibodies in blocking buffer 
overnight at 4 °C and  CF488A, CF568, or CF660C (Biotum) conjugated secondary 
antibodies. Images were acquired on a CSU-X spinning disc confocal microscope 
(Intelligent Imaging Innovations) with an HQ2 CCD camera (Photometrics) using a 
100× objective. 
Quantitative analysis of lysosomal PGRN and endocytosed PGRN and PSAP- Images 
were processed and analyzed by ImageJ program as previously described (Zhou et al., 
2015). Briefly, the colocalization between PGRN and lysosomal markers, LAMP1, was 
quantified by using JACoP plugin. To quantify the endocytosed PGRN and PSAP, the 
entire cell was selected and the fluorescence intensity was measured directly by ImageJ.  
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Ethical Approval and Consent to participate- All applicable international, national, 
and/or institutional guidelines for recombinant DNA and cell lines were followed.  The 
work under protocol (MUA#: 15965) were approved by the Cornell University 
Institutional Biosafety Committee (IBC). 
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APPENDIX II 
 
WDR41 LOCALIZES TO THE GOLGI AND ENDOPLASMIC RETICULUM AND 
OVEREXPRESSION OF WDR41 INDUCES VESICLE FORMATION 
 
 
Summary  
 WDR41 is an approximately 50 kDa protein comprised almost entirely of WD-
repeat and binds to the SMCR8-C9orf72 dimer. While knockout of WDR41 in a mouse 
model does not replicate the immune phenotype observed in SMCR8 and C9orf72 
knockout mice, it is the only component of this complex to show clear localization to 
membrane structure in the cell. We previously reported that WDR41 is enriched at the 
Golgi, but C9orf72 and SMCR8 appear mostly cytosolic. Here, I present evidence that 
WDR41 also resides at the endoplasmic reticulum (ER) and that strong overexpression 
of WDR41 is sufficient to produce WDR41-positive vesicles of unknown identity. 
Figure AII-1 shows the localization of WDR41-GFP expressed in HeLa cells for 
20 hours. As shown in Chapter 2, fixed HeLa cells with WDR41 overexpressed show 
clear WDR41 enrichment at the Golgi, stained by GPP130 here. However, viewing 
WDR41-GFP in live cells allows more structural detail to be discerned. In live images, 
WDR41 colocalizes with Sec61-β, a marker of the ER. This suggests that WDR41 may 
traffic between the Golgi and ER and that ER localization is lost during the fixation 
process (Figure AII-1). 
 In addition to this Golgi and ER localization, the overexpression of WDR41 
occasionally (5% of cell population) seems to induce the formation of novel vesicles of 
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unknown identity (Figure AII-2). The presence of these vesicles appears to correlate 
with the expression level of WDR41. This data confirms that WDR41 is indeed 
interacting with membranes in the cell, though it is unclear how WDR41 is recruited 
and what role WDR41 plays there. Whether vesicular phenomena is dependent on 
C9orf72 and SMCR8 is also uncertain. Overexpression of WDR41 in C9orf72-/- or 
SMCR8-/- cells may help to answer whether this effect is due to the C0orf72-SMCR8-
WDR41 complex or a separate function of WDR41. So far, I have not been able to 
identify any common organelle markers on these WDR41-positive vesicles.  
 While WDR41 likely acts as a scaffolding protein, as many other WD-repeat 
proteins do, for SMCR8 and C9orf72, the presence of a cellular localization and 
phenotype may provide an alternative route to understanding the function of this protein 
complex. Better characterization of these WDR41-positive vesicles may suggest 
additional binding partners that are needed to carry out vesicle formation, such as Rab 
GTPases. Additionally, whether or not WDR41 is able to recruit C9orf72 and SMCR8 
to the Golgi or ER is still unclear, but will provide insight into the dynamics of the 
C9orf72-SMCR8-WDR41 complex.  
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Figure AII-1: WDR41 localizes to the Golgi and ER. (Top panel) WDR41-GFP 
overexpressed in HeLa cells. These cells were fixed in PFA and stained for a Golgi 
marker, GPP130. (Bottom panel) WDR41-GFP co-expressed in HeLa cells with 
mCherry-Sec61β to label the ER. These images are taken with live cells.  
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Figure AII-2: Overexpression of WDR41 results 
in the appearance of WDR41-positive vesicles. 
Top: WDR41 most commonly localizes with a 
cytosolic/ER appearance. Bottom: Examples of 
cells with WDR41-postive vesicles. 
 
